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ABSTRACT 
 
 
Congenital nephrotic syndrome of the Finnish type (NPHS1, CNF) is an autosomal recessive 
disease, enriched in the Finnish population. NPHS1 is caused by a mutation in the NPHS1 
gene. This gene encodes for nephrin, which is a major structural component of the slit 
diaphragm connecting podocyte foot processes in the glomerular capillary wall. The podocyte 
and slit diaphragm are crucial for glomerular sieving. In NPHS1, the genetic defect in nephrin 
leads to heavy proteinuria starting already during the foetal period. Finnish NPHS1 patients are 
nephrectomized at infancy, and after a short period of dialysis the patients receive a kidney 
transplant, which is the only curative therapy for the disease. NPHS1 kidneys serve as a unique 
human model for studies of the pathology of proteinuric kidney diseases.  
In this thesis, we examined the cellular and molecular mechanisms leading to the progression 
of glomerulosclerosis and tubulointerstitial fibrosis in NPHS1 kidneys. We evaluated the 
structural and phenotypic changes of the glomerular endothelium and searched for possible 
signs of injury and loss of peritubular capillaries (PTCs). We characterized the mesangial 
changes and investigated the expression of the major molecular factors related to glomerular 
sclerosis. The role of oxidative stress in the progression of fibrosis in NPHS1 kidneys was 
also investigated. 
 
Mesangial expansion and capillary obliteration were observed in practically all glomeruli in 
NPHS1 kidneys removed at infancy. To obtain more insights into mesangial pathology, we 
characterized the mesangial changes and studied the expression of the major molecular factors 
related to glomerular sclerosis. The proliferation of mesangial cells (MCs) was evident in 
practically all NPHS1 glomeruli, and this hyperplasia explained most of the mesangial 
expansion, although the proliferation rate was quite low. The accumulation of extracellular 
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matrix (ECM) proteins was detected also in the mesangium of NPHS1 kidneys. Collagen IV, 
the main structural component of normal mesangium, mostly accounted for the ECM 
accumulation in glomeruli in both mild and severe lesions. We further characterized the 
expression of the most important profibrotic mediators controlling the MC function. The 
expression of transforming growth factor-beta (TGF-) and its downstream mediator 
connective tissue growth factor (CTGF) were both  moderately upregulated in NPHS1 
kidneys. We also observed the activation of the TGF- signaling pathway, which suggests 
that TGF- has an important role in regulating glomerulosclerosis in NPHS1 kidneys. These 
results indicate that severe glomerular sclerosis can develop without major qualitative cellular 
or molecular changes in the mesangium. 
 
The average diameter of capillary cross-sections in NPHS1 kidneys was 20-30% narrower 
than in controls. The endothelial cell surface area was decreased up to 60% in NPSH1 
kidneys. Intracapillary cells in NPHS1 kidneys showed neither proliferative nor apoptotic 
activity. It seemed that NPHS1 glomeruli suffered from some degree of hypoxia since they 
showed abundant expression of hypoxia inducible factor-1-alpha (HIF-1). The overall 
structure of endothelial cells and their adherence to the glomerular basement membrane 
(GBM) were quite well preserved in NPHS1 kidneys. The endothelium in NPHS1 glomeruli 
showed regular fenestrae resembling the endothelium in control kidneys. However, we 
observed local lesions with marked endothelial blebs filled with cellular organelles 
(endotheliosis). The bleb size varied, but total obstruction of capillary lumen was not 
observed. These results indicate that ultrastructural lesions in endothelial cells are obvious, 
but overall the glomerular endothelium is quite resistant to podocyte injury and the nephrotic 
state in NPHS1 kidneys. 
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Mesangial expansion and glomerular capillary obliteration develop early in NPHS1 kidneys, 
possibly reducing blood flow into PTCs. Sclerotic glomeruli surrounded by inflammatory 
cells, tubular dilatation, interstitial fibrosis and obliterating arteries were observed with 
advancing age. We also observed that the density of PTCs was slightly reduced in NPHS1 
kidneys, and the PTC loss was associated with expression of vimentin, which is an early 
marker for tubulointerstitial lesions. The loss of PTCs was clearly associated with the 
development of interstitial fibrosis. A higher amount of HIF-1 was found in the 
tubulointerstitium of NPHS1 kidneys, implicating low oxygen tension. Fibrin depositions or 
thrombi were not observed in the peritubular capillaries of NPHS1 kidneys. The inflammatory 
response of PTCs was seen as an upregulation of intercellular adhesion molecule-1 (ICAM-1) 
expression. These results suggest that hypoxia in the tubulointerstitium caused by 
hypoperfusion of glomerular and peritubular capillaries and the rarefaction of PTCs may be 
important for the rapid progression of fibrosis in the kidneys of NPHS1 patients. 
 
We further examined the activation of the renin-angiotensin system (RAS) and reactive 
oxygen species (ROS) in NPHS1 kidneys.  Oxidation of polysaturated fatty acids, as well as 
decreased antioxidant enzyme activites, was seen in NPHS1 kidneys. In addition, a significant 
elevation in the expression of p22phox, the subunit of nicotinamide adenine dinucleotide 
phosphate (NAP(D)H) oxidase, was noted in the NPHS1 kidneys, indicating the presence of 
oxidative stress. We observed that the mRNA transcript levels of RAS-related molecules were 
upregulated in NPHS1 kidneys. However, only the expression of angiotensin II (Ang II) was 
clearly upregulated at the protein level. 
 
In conclusion, our data indicate that severe podocyte damage most probably affects the cross-
talk between podocytes and MCs, leading to the activation of mesangial cells in NPHS1 
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kidneys. MC proliferation and the accumulation of ECM are associated with the obliteration 
of glomerular capillaries, causing the reduction of circulation in PTCs. The injury and 
rarefaction of PTCs result in impairment of oxygen and nutrient delivery to the tubuli and 
interstitial cells, which correlates with the fibrosis, tubular atrophy and oxidative stress 
observed in NPHS1 kidneys.  
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REVIEW OF THE LITERATURE 
 
1. Structure and function of the kidney 
The kidneys are two bean-shaped organs located in the retroperitoneal space behind the 
abdominal cavity (Figure 1A). The essential function of the kidney is to preserve constancy of 
body fluids and electrolytes by removing water and potentially harmful metabolic end-
products (e.g. urea, uric acid, phosphates, sulphates), while preserving essential solutes (e.g. 
sodium, potassium, chloride, bicarbonate, sugar, amino acids). The kidneys also have an 
important role in maintenance of proper blood pressure and in the production and secretion of 
enzymes and hormones such as renin, erythropoietin and the active form of vitamin D (Kon et 
al. In: Pediatric Nephrology 2004, Briggs et al In: Primer on Kidney Diseases 2005). 
             
Figure 1. (A) Anatomy of a kidney and (B) the structure of the functional unit, the nephron. 
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The functional unit of the kidney is a nephron (Figure 1B). Each of the approximately one 
million nephrons in the human kidney consists of a glomerulus, proximal tubule, loop of 
Henle, distal tubule and collecting duct, each with a typical cellular appearance and special 
functional characteristics (Briggs et al. In: Primer on Kidney Diseases 2005).    
 
The filtration process begins in the renal glomerulus, where plasma is ultrafiltered under 
pressure through a filtration barrier, a semipermeable glomerular capillary wall (Figure 2). 
Glomerular sieving is based on the size and charge of the macromolecule. While this complex 
glomerular filter is freely permeable to water and small dissolved solutes, there is an efficient 
selectivity that restricts most of the proteins (albumin, 69 kDa and larger proteins) as well as 
blood cells from crossing the capillary wall (Deen et al. 2001). Filtration also depends on 
ionic charge, and negatively charged proteins, such as albumin, are retained to a greater extent 
than predicted by size alone. The magnitude of this filtration process is enormous and requires 
a high rate of renal blood flow (RBF). The entire plasma volume is cycled through the 
glomerular system 20 times per hour. The glomerular filtrate undergoes a series of 
modifications in tubuli and the collecting duct before forming the final urine. These changes 
consist of reabsorption and secretion of solutes by the tubular epithelial cells. Even though 
approximately 180 litres of primary filtrate, i.e. primary urine, is produced every day, the final 
urine volume is only 1-1.5 litres per day (Renkin et al 1974, Briggs et al. In: Primer on 
Kidney Diseases 2005).   
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Figure 2. Structure of the glomerulus. Primary urine is produced in the glomerulus, which 
consists of a capillary tuft surrounded by a urinary space and Bowman’s capsule. 
 
1.1 Glomerulus 
 
The kidney is an anatomically complex organ, consisting of many different types of highly 
specialized cells, arranged in an organized three-dimensional pattern. The glomerulus consists 
of a capillary tuft with endothelial cells adherent to the glomerular basement membrane 
(GBM) surrounded by a layer of epithelial cells called the glomerular podocytes (Figure 3). 
The major molecular constituents of GBM are collagen IV, laminin-entactin/nidogen 
complexes and proteoglycans. Collagen IV provides a scaffold for the other structural 
macromolecules by forming a network via interactions between specialized N- and C-terminal 
domains. Laminin-entactin/nidogen complexes self-associate into less-ordered aggregates. 
These two molecular assemblies appear to be interconnected, presumably via binding sites on 
the entactin/nidogen molecule. In addition, proteoglycans are anchored into the membrane, 
providing the overall negative charge of the GBM. (Paulsson 1992, Aumailley 1995, Erickson 
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et al. 2000). Podocytes are large, highly differentiated cells that form an array of lacelike foot 
processes over the outer surface of the capillaries. An outer epithelial capsule, called 
Bowman’s capsule, acts as a pouch to capture the filtrate and direct it into the opening of the 
proximal tubule. The capillaries are held together by a stalk of cells, called the glomerular 
mesangium (Tisher et al. 1991). 
 
 
1.1.1 Glomerular endothelial cells  
 
The glomerular capillary endothelial cells are highly fenestrated cells lining the glomerular 
capillary. The endothelial cell fenestrae (70-100 nm in diameter) face both the GBM and the 
mesangial region (Rostgaard et al 2002, Hjalmarsson et al. 2004, Satchell et al. 2009). The 
fenestrae and the whole luminal side of the cell are covered by a special glycocalyx with the 
negative charge due to sialic acid-containing glycoproteins and lipids (Hjalmarsson et al. 
2004, Reitsma et al. 2007, Weinbaum et al. 2007). Endothelial cells have an active role in 
controlling coagulation, inflammation and immune processes within the glomerulus. The 
plasma components pass freely through the endothelial fenestrae, whereas the blood cells and 
larger macromolecules are retained within the capillaries due to a size selective barrier and the 
negative charge of the endothelial cells (Endemann et al. 1992).  
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Figure 3. Cross-section of a glomerular capillary showing the three glomerular cells. 
1.1.2 Podocytes and slit diaphragm  
 
Visceral epithelial cells (podocytes) form the outermost layer of the glomerular filtration 
barrier. The podocytes enclose the capillaries in a comb-like fashion, where the adjacent foot 
processes form an interrupted sheet around the capillaries (Kerjaschki 2001, Pavenstadt et al. 
2003). The podocyte is divided into four segments: cell body, major processes, secondary 
processes and foot processes. The major processes have an abundant cytoskeleton composed 
mainly of microtubules and intermediate filaments. They are responsible for the maintenance 
of the complex cytoarchitecture of the podocyte, and they take care of the molecular transport 
between the cell body and the foot processes. The foot processes form the most peripheral 
part of the podocytes. The cytoskeleton of the foot processes is mainly composed of actin-
microfilaments. These filaments run parallel to the longitudinal axis of the foot processes and 
interact with many associated proteins, such as myosin, synaptopodin and alpha-actinin-4 
(Mundel et al. 2002, Jalanko 2003). Maintenance of the podocyte architecture also requires 
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that the foot processes adhere to the GBM. This is controlled by the expression of integrins 
and dystroglycans, which are connected to the actin cytoskeleton in the podocyte. They also 
bind to several components of the GBM (Adler 1992, Raats et al. 2000). 
 
         
 
Figure 4.  Schematic illustration of podocyte foot processes and the intervening slit 
diaphragm (SD). (a) Overview of the structural components, including capillary endothelial 
cells, GBM and podocyte foot processes (FPs). The SD connects neighbouring foot processes. 
(b) A schematic diagram showing molecules related to the nephrin-NEPH-podocin complex 
at SD. (c) Molecules at the podocyte-GBM interface and linkage to FP actin cytoskeleton. 
Adapted from Zenker et al. (2009), J Mol Med 87: 849-857. Reproduced with permission 
from the copyright holder.        
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The foot processes are connected just above the GBM by the slit diaphragm (SD), which 
bridges the filtration pores between the adjacent podocyte foot processes. The podocyte SD 
serves as a final gate on restricting the passage of molecules into urine.                                                                     
The filtration pore has a width of 20-50 nm (Tryggvason et al 2003), and it forms a zipper-
like structure, as originally reported by Rodewald and Karnovsky, 1974. The SD consists of 
an extracellular meshwork of proteins anchored at the luminal membrane of the foot 
processes (facing Bowman’s space) (Figure 4). This specialized structure of cell-cell contact 
seems to represent the main selective filter barrier in the kidney. The SD proteins form a 
multi-protein complex that forms a mesh-like structure, connects the SD intracellulary to the 
actin cytoskeleton, and participates in signalling as well as the turnover of SD (Benzing 2004, 
Tryggvason et al. 2006). Most of these proteins are also essential for glomerular sieving, as 
mutation or inactivation of their genes lead to proteinuria (Table 1). The first SD protein to be 
identified was nephrin, the gene of which is mutated in congenital nephrotic syndrome of the 
Finnish type (CNF, NPHS1) (Kestilä et al. 1998). In addition to nephrin, other proteins, such 
as nephrin-related protein 1 and 2 (Neph 1, Neph 2), FAT1, FAT2, dendrin, densin, P-
cadherin, VE-cadherin and catenins, have been localized to the SD (Figure 4) (Gerke et al. 
2005, Huber et al. 2005, Patrakka et al. 2007, Heikkilä et al. 2007, Holthöfer 2007, Harita et 
al. 2008, Fukasawa et al. 2009). 
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Table 1. Classification of genetically determined hereditary proteinuric syndromes. 
___________________________________________________________________________ 
Disease  Gene Protein        Inheritance            Age of onset (years)__ 
 
Congenital nephrotic  NPHS1 Nephrin                 AR      0-0.5 
syndrome of the Finnish 
type (CNF, NPHS1) 
 
Nephrotic syndrome type 2 NPHS2 Podocin                 AR      0-3 
(steroid-resistant NS) 
 
Focal segmental glomerulo- ACTN Actinin 4                 AD      5-40 
sclerosis (FSGS) CD2AP CD2-associated                 AD/AR 
   protein 
  TRPC6 Transient receptor             AD 
   potential cation 
   channel C6 
 
Familial DMS  NPHS3 Phospholipase C1            AR      0.5-4 
 
Denysh-Drash syndrome WT-1 WT1 protein                 AD      0.5-4 
  Frasier syndrome 
  Isolated DMS 
 
Nail-patella syndrome LMX1B LIM homeobox                 AD      2-50 
   transcription factor  
 
Pierson syndrome LAMB2 Laminin 2                 AR      0-0.5 
 
Schimke immuno-osseous SMARCAL1 SMARCA-                 AR      0.5-6 
dysplasia (SIOD)  like protein 
 
Galloway-Mowat syndrome Unknown Unknown                 AR      0-10 
 
CDG syndrome  PMM2 Phosphomannomutase 2   AR                             Variable 
  ALG1 -1,4-Mannosyltrans- 
   ferase 
 
(Nephro)-Sialidosis NEU1 Neuraminidase                   AR      Variable 
 
Coenzyme Q10 deficiency COQ2 Parahydroxybenzoate-       AR      Variable 
   polyprenyltransferase 
  PDSS2 Prenyl diphosphate 
    synthase subunit 2 
 
Mitochondrial disorders mtDNA Mitochondrial                  Mitochondrial     Variable 
  tRNALeu transfer RNA 
tRNATyr 
__________________________________________________________________________________________ 
 
AD autosomal dominant, AR autosomal recessive, DMS diffuse mesangial sclerosis, FSGS focal and segmental 
glomerulosclerosis, NS nephrotic syndrome, 
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Nephrin is a 1241 amino acid long transmembrane cell adhesion protein of the 
immunoglobulin family with a molecular size of approximately 185 kDa. Nephrin contains a 
short (154 amino acids) intracellular domain, and an extracellular domain with eight distal 
IgG-like motifs and one proximal fibronectin type III-like motif. In kidneys, nephrin is 
synthesized in podocytes (Kestilä et al. 1998) and localized at SD (Ruotsalainen et al. 1999). 
 
Nephrin molecules are proposed to interact in the SD through homophilic interactions, thus 
forming a zipper-like structure with pores on both sides of the central density (Ruotsalainen et 
al. 1999, Tryggvason 1999, Khosnoodi et al. 2003). The extracellular domain of human 
nephrin contains ten potential N-glycosylation sites in its amino acid sequence. N-
glycosylation of nephrin plays a crucial role in the molecular folding of the protein and is also 
essential for plasma membrane localization (Yan et al. 2002). Neph1, Neph2 and Neph3 are 
three closely related transmembrane proteins to nephrin. Neph1 has been identified as a 
binding partner of nephrin (Ihalmo et al. 2003, Sellin et al. 2003). It has been suggested that 
interactions involving nephrin and neph1 are required for an intact SD structure (Barletta et 
al. 2003, Gerke et al. 2003, Liu et al. 2003). Neph1-mediated cis interactions may also link 
and stabilize nephrin molecules to induce nephrin-dependent signaling processes (Lahdenperä 
et al. 2003). 
  
Recent results have suggested that nephrin is involved in signalling processes that are 
important for podocyte function, survival and differentiation (Patrakka et al. 2007, Zenker et 
al. 2009). The intracellular domain of nephrin is associated with linker/scaffolding proteins 
and signaling molecules (Huber et al. 2005). It is indirectly connected to actin cytoskeleton in 
podocytes (Faul et al. 2007). Tyrosine phosphorylation of the cytoplasmic tail of nephrin and 
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neph1 initiates a signalling cascade in the podocyte (Benzing 2004). Src kinase Fyn is 
identified as one of the tyrosine kinases responsible for nephrin phosphorylation that further 
regulates podocyte morphology via the Nck family adaptor proteins (Jones et al. 2006, Verna 
et al. 2006). Adaptor proteins Nck1 and Nck2, which interact with nephrin and actin via their 
SH2 and SH3 domains, are involved in the regulation of actin cytoskeletal dynamics. 
Distinctly, SH2 domains of Nck adaptors link nephrin to the cytoskeleton by interacting with 
phosphotyrosines, whereas the SH3 domains mediate actin polymerization. Furthermore, the 
phosphorylation of nephrin by Fyn kinase enables the binding of phosphoinositide 3-OH 
kinase (PI3K) to the intracellular nephrin-podocin-CD2AP complex (Huber et al. 2003). PI3K 
is a heterodimer comprising a regulatory subunit p85 and a catalytic subunit p110. The p85 
subunit recognizes the phosphorylated nephrin and allows the p110 subunit to phosphorylate 
phospholipids at the inner leaflet of the lipid bilayer and further activate the serine-threonine 
kinase AKT. AKT promotes cell survival and counteracts apoptotic stimuli in podocytes 
(Huber et al. 2003). Nephrin has also been reported to interact with various junctional 
adhesion and scaffolding molecules such as IQGAP1 (IQ motif-containing GTPase-activating 
protein) (Liu et al. 2005, Lehtonen et al. 2005), MAGI-2 (membrane-associated guanylate 
kinase inverted 2), CASK (calcium/calmodulin-dependent serine protein kinase), -actin, II 
spectrin and II spectrin (Lehtonen et al. 2005). The biological significance of these 
interactions is not yet known. 
         
1.1.3 Mesangial cells 
 
The mesangial cell was recognized as a distinct cell less than 80 years ago (Zimmermann 
1933). It is one of the three major cell types present in the normal glomerulus and constitutes 
approximately 30-40% of the total glomerular cell population (Olivetti et al. 1977). Mesangial 
cells provide structural support for the capillary loops. They are irregular in shape and a 
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number of primary processes extend from the cell body. The mesangial matrix contains 
collagens, laminin, entactin, nidogen, fibronectin and heparan sulphate proteoglycan (Truong 
et al. 1994, Schlöndorff et al. 2009). Mesangial cells are abundant in myosin and actin 
filaments, and they have contractile properties. They also show macrophage-like phagocytic 
activity. The mesangium-endothelial cell interface is rather loose and leaky, allowing plasma 
flow into the mesangium. Mesangial cells modulate glomerular filtration with their contractile 
properties, regulated by vasoactive peptides, growth factors and cytokines (Elger et al. In: 
Oxford textbook of clinical nephrology 2005). They also synthesize and degrade matrix 
components, are capable of handling and taking up macromolecules and participate in the 
repair of glomerular injury (Pröls et al. 1999).  
 
1.2 Renal tubuli 
 
Renal tubuli originate from metanephric mesenchyme are differentiated into the proximal 
tubule, the loop of Henle and the distal tubule (Sariola et al In: The kidney. From normal 
development to congenital disease, 2003). The proximal tubule consists of three 
morphologically different segments: Bowman’s capsule, proximal convoluted tubuli and 
proximal straight tubuli, and is characterized by a prominent brush border, which increases 
the membrane surface area by a factor of about 40-fold.  The major function of the proximal 
tubule is the reabsorption of almost all of the filtered glucose, amino acids, phosphate and 
bicarbonate and approximately 60% of the sodium, chloride and water (Figure 5) (Briggs et 
al. In: Primer on Kidney Diseases 2005).  
 
The small amount of albumin and other proteins filtered into primary urine is reabsorbed in 
proximal tubular cells. Megalin and cubilin are endocytic receptors highly expressed in the 
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luminal surface of the proximal tubular cells. The filtered albumin binds to the 
megalin/cubulin receptor complex in clathrin-coated pits, where it undergoes receptor-
mediated endocytosis (Tojo et al. 1992, Christensen et al. 2001). Endocytic vesicles detach 
from the apical membrane and deliver the albumin-megalin-cubulin complex to a sorting 
endosomal compartment, where albumin dissociates and megalin and cubulin are recycled to 
the plasma membrane. Albumin subsequently reaches the lysosomal compartment, where it is 
cleaved and the amino acids reabsorbed or peptide fragments returned to the tubular lumen 
(Jefferson et al. 2008). 
                           
Figure 5. Function of the tubular cell as exemplified by glucose reabsorption. Fluid in the 
filtrate entering the proximal convoluted tubule is reabsorbed to a great extent into the 
peritubular capillaries. This process is driven by sodium transport from the lumen into the 
blood. The Na+/K+ ATPase in the basolateral membrane of the epithelial cells form the 
electrical gradient. The reabsorption of glucose (attached to Na
+
 ion) in the apical membrane 
of the epithelial cells occurs through the SGLT cotransporters, and through the GLUT 
channels at the basolateral membrane. Adapted from Jalanko et al. (1998), Duodecim 114: 
153-161. Reproduced with permission from the copyright holder.         
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The loop of Henle is the portion of the nephron that leads from the proximal convoluted 
tubule to the distal convoluted tubule. The loop of Henle has a hairpin bend in the renal 
medulla, and the main function of this structure is to create a concentration gradient in the 
medulla. It consists of a straight portion of the proximal tubule, thin descending and 
ascending limbs and thick ascending limbs. The thin limbs are shallow epithelia without the 
prominent mitochondria of more proximal segments, whereas the thick limb is taller 
epithelium containing basolateral infoldings and well-developed mitochondria (Jones et al. In: 
Pediatric Nephrology). 
 
The thick ascending limb of Henle’s loop continues as a distal tubule. It is divided into the 
distal convoluted tubule and connecting tubule. Both have well-developed basolateral 
infoldings with abundant mitochondria. The distal tubule is impermeable to water and urea, so 
that the urea concentration in the tubular lumen remains high. The distal tubule and collecting 
duct take care of the formation of final urine by reabsorbing and excreting sodium, potassium, 
proteins and water, according to the needs of the body (Gartner et al. 1997a). 
                            
1.3 Renal cortical interstitium 
 
The renal cortical interstitium is situated in the space between the basement membranes of 
tubular epithelial cells and nutritive capillaries. Whilst the interstitium of the cortex occupies 
only a small volume fraction, its location ensures its involvement in the massive fluid and 
solute exchange that occurs normally between tubules and blood vessels (Kaissling et al. 
1996). The renal cortical interstitium may be divided into peritubular, periarterial and special 
interstitia (extra- and intraglomerular mesangium). The renal interstitium is composed of cells 
and extracellular matrix with proteoglycans, glycoproteins and interstitial fluid (Lemley et al. 
1991). The interstitial cells have an important role in the modelling of the extracellular matrix, 
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production of regulatory substances and immune responses (Alcorn et al. 1999). Renal 
fibroblasts and dendritic cells are the most abundant interstitial cell types, and they form 
closely entangled networks in the interstitium. Other cell types, such as macrophages and 
lymphocytes, are only occasionally found in healthy interstitium, but they invade the 
interstitial spaces under inflammatory conditions (Eddy 2005). 
 
Fibroblasts in the interstitium provide the ―skeleton‖ of the tissue and maintain its three-
dimensional architecture. Fibroblasts are interconnected by junctions and connected to 
basement membranes of vessels and tubules by focal adhesions. In the renal cortex, the 
peritubular fibroblasts produce erythropoietin and are distinguished from other interstitial 
cells by their prominent F-actin cytoskeleton, abundance of rough endoplasmic reticulum, and 
ecto-5’-nucleotidase expression in their plasma membrane. Fibroblasts synthesize many of the 
constituents of fibrillar ECM, such as fibronectin and types I, III and V collagen, and they are 
also a major source of ECM-degrading proteases such as matrix metalloproteinases (MMPs) 
(Rodemann et al. 1991, Tomasek et al. 2002).  
 
Dendritic cells belong to the mononuclear phagocyte system, acting at the cross-roads of 
innate and adaptive immunity, self-tolerance and tissue homeostasis (Soos et al. 2006, John et 
al. 2007). Unlike fibroblasts, the pericaryon of dendritic cells is large and rounded and 
confines a round-shaped nucleus and most cell organelles. Dendritic cells have been 
recognized by their expression of major histocompatibility complex (MHC) class II antigens 
and have been isolated on account of their membrane expression of CD11c (Kruger et al. 
2004). In the healthy kidney, dendritic cells are present in their immature phenotype, with 
comparingly low levels of MHC class II antigens and of co-stimulatory proteins (Kruger et al. 
2004), but with a high capacity for uptake of antigens (Dong et al. 2005).  
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1.4 Renal circulation and its regulators 
 
Renal arteries arise from the side of the abdominal aorta, supplying around 20% of the cardiac 
output to the kidneys. After entering the kidney, the renal artery bifurcates several times and 
then divides into the arcuate arteries, which run in an arch-like fashion along the border 
between the cortex and the outer medulla. The arcuate vessels give rise, typically at right 
angles, to interlobular arteries, which run to the surface of the kidney. The afferent arterioles, 
which supply the blood to glomeruli, are followed by the interlobular vessels. The renal 
circulation divides into two separate capillary beds: the glomerular bed and the peritubular 
capillary bed (Figure 6). These two capillary networks are arranged in series so that all the 
renal blood flow passes through both sequentially. As blood leaves the glomerulus, the 
capillaries coalesce into the efferent arteriole, but almost immediately the vessels birfurcate 
again to form the peritubular capillary network. This second network of capillaries is the site 
where tubular reabsorbate is returned to the circulation. The pressure in the glomerular 
capillary bed is rather high (about 40-60 mm Hg), while the pressure in the peritubular 
capillaries is similar to that in capillary beds elsewhere in the body (about 5-10 mmHg) 
(Briggs et al. Primer on Kidney Diseases 2001). 
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Figure 6. The microvasculature of the nephron consists of the glomerular and the peritubular 
capillary networks. Adapted from Nangaku, J Am Soc Nephrol (2006) 17: 17-25. Reproduced 
with permission from the copyright holder.                                                                
 
Renal autoregulation, or the kidney’s intrinsic ability to maintain a constant renal blood flow 
(RBF) and glomerular filtration rate (GFR), serves to protect nephron function, despite 
changes observed in renal perfusion pressure. Autoregulation occurs in interlobular arteries, 
side branches of arcuate arteries, and afferent and efferent arterioles. The regulation of renal 
circulation is controlled by numerous factors, including intrinsic or myogenic autoregulation 
(Bidan et al. 2009), tubuloglomerular feedback (Cupples et al. 2007) and various vasoactive 
factors (Nangaku et al. 2007, Sadowski et al. 2008). 
In the classic Renin-Angiotensin System (RAS), circulating renal-derived renin cleaves 
hepatic-derived angiotensinogen to form the decapeptide angiotensin I, which is converted to 
the active component of the renin-angiotensin system, angiotensin II (Ang II), by angiotensin-
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converting enzyme (ACE). Renin is secreted from the juxtaglomerular apparatus of afferent 
arterioli in response to glomerular underperfusion or reduced sodium intake, or in response to 
stimulation of the local vascular wall RAS system (Muller et al. 1998). The effects of Ang II 
are mediated primarily by the plasma membrane receptors AT1 and AT2 (Rüster et al. 2006). 
Ang II has a direct effect on the proximal tubules to increase Na
+
 reabsorption by stimulation 
of Na+/H+ exchange. It also affects the salt balance indirectly by stimulating the production 
and release of aldosterone from the zona glomerulosa of the adrenal gland, which results in a 
further rise in blood pressure from aldosterone-mediated sodium and water retention (Valles 
et al. 2005). In addition, it plays an important physiological role in sympathetic nervous 
activity and thirst response. As a potent vasoconstrictor, Ang II may also reduce RBF in renal 
arteries as well as in afferent and efferent arterioles. High concentrations of Ang II can 
constrict the glomerular mesangium, reducing the glomerular capillary pressure and the area 
for glomerular filtration (Hamming et al. 2007). Ang II also affects the glomerular podocytes 
by reducing nephrin expression (Durvasula et al. 2006). 
 
Endothelin-1 (ET-1) is an endothelial cell-derived, potent vasoconstrictive peptide 
containing 21 amino acids (Luscher et al. 1992, Simonson 1993). Three isopeptides of 
endothelin (ET-1, ET-2 and ET-3), encoded by separate genes, have been identified 
(Davenport 2006). Endothelial ET-1 synthesis is activated by vasoactive hormones, growth 
factors, hypoxia, shear stress, lipoproteins, free radicals, and endotoxin, and is inhibited by 
nitric oxide (NO), natriuretic peptides, heparin, and prostaglandins (Naicker et al. 2001). 
Endothelins signal through two receptor subtypes, ETA and ETB. The ETA receptor is 
preferentially used by ET-1, but not by ET-3, whereas the ETB receptor is used equally by 
ET-1 and ET-3. The vasoconstrictor effects of endothelin are mediated primarily by ETA 
receptors, but ETB receptors, located on vascular smooth muscle, also contribute to the 
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vasoconstrictor effects of this peptide (Motte et al. 2006). ET-1 contracts afferent and efferent 
arterioles equally, thus reducing both renal plasma flow and GFR. ET-1 also activates 
production of prostacyclin and thromboxane A2 (Naicker et al. 2001, Cediel et al. 2002). The 
overall cardiovascular effect of endogenous ET-1 depends on the balance between ETA- and 
ETB-mediated effects. Activation of vascular smooth muscle ETA receptor causes 
vasoconstriction and tends to elevate blood pressure, whereas activation of endothelial and 
renal ETB receptors promotes vasodilatation and natriuresis and tends to decrease blood 
pressure (Taddei et al. 2001). 
 
 
Nitric oxide (NO) is an endothelium-derived gas, synthesized from L-arginine by the 
endothelial isoform of NO synthase (NOS). NO is extremely labile with a half-life of less than 
four seconds in biological solutions (Moncada et al. 1993). NO is a vasodilator and the 
balance between NO, various endothelium-derived vasoconstrictors and the sympathetic 
nervous system maintains physiological blood vessel tone (Vallance et al. 1989). In addition, 
NO suppresses platelet aggregation, leukocyte migration and cellular adhesion to the 
endothelium. It attenuates vascular smooth muscle cell proliferation and migration as well as 
inhibits the expression of certain adhesion molecules. NO also has an influence on production 
of superoxide anion. 
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2. Pathophysiology of chronic kidney diseases 
Chronic kidney disease (CKD) is defined as a progressive loss of renal function over a period 
of months or years. The decline in renal function in chronic renal failure is based on the 
progressive loss of viable nephrons. Glomerular diseases are the major cause of CKD, 
including diabetic nephropathy, non-inflammatory nephrotic disorders, IgA nephropathy and 
other forms of glomerulopathies as well as systemic vasculitis. They fall pathophysiologically 
into two major categories: glomerulosclerosis (accumulation of ECM in the glomeruli and the 
scarring of the capillary blood vessels) and glomerulonephritides (characterized by the 
inflammation of the glomeruli or small blood vessels in the kidneys) (Couser 1999, Abbate et 
al. 2006). All glomerular kidney disorders, with the exception of minimal change disease 
(MCNS) are characterized by a progressive decline of renal function in association with 
glomerulosclerosis and tubulointerstitial fibrosis (Peterson et al. 1995, Remuzzi et al. 1997). 
This almost universal association seems to suggest that the progressive loss of kidney 
function results from a fibrogenic mechanism that serves as a final common pathway to end-
state renal disease (ESRD). It starts with the initial insult to the glomerulus, initiating a 
cascade of events that includes an early inflammatory phase followed by a fibrogenic 
response in the glomerular and the tubulointerstitial compartments of the kidneys (Figure 7) 
(Hostetter 2003, Segerer et al. 2007).  
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Figure 7. Schematic procedure for the progression of renal disease. 
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2.1 Proteinuria and chronic kidney disease 
  
Proteinuria is a condition characterized by the presence of greater than normal amounts of 
protein in urine. The normal rate of excretion of protein in urine is 80 + 24 mg/24 h in healthy 
individuals. Over 95% of normal adults excrete less than 130 mg/day of protein. Nephrotic-
range proteinuria in adults is characterized by protein excretion of 3.5 g or more per day, 
while nephrotic-range proteinuria in children has protein excretion of more than 40 mg/m
2
/h. 
(Jefferson et al. 2008). Proteinuria can be classified into two main pathophysiological 
categories: glomerular proteinuria and tubular proteinuria. Glomerular proteinuria is the result 
of a disturbance in the permselectivity of the glomerular capillary wall, leading to the 
filtration of abnormally high amounts of plasma proteins. These filtrated proteins saturate the 
maximal tubular reabsorptive capacity and are excreted into the urine (Elger et al. In: Oxford 
Textbook of Clinical Nephrology 2005, Guignard et al. In: Pediatric Nephrology 2004). 
Glomerular proteinuria can be functional or pathological. Mild functional proteinuria is due to 
increased hydrostatic pressure or an altered glomerular filtration coefficient, e.g. stress, 
exercise, fever, excitement and congestive heart failure. Pathological glomerular proteinuria is 
due to renal disease and can be selective (resulting in loss of small molecular weight proteins 
such as albumin) or non-selective (with loss of larger molecular weight proteins such as 
globulins). With glomerular disease, proteinuria usually starts as selective, with only albumin 
being lost (due to its small size). As the disease progresses the glomerular filter barrier is 
further disrupted, resulting in a non-selective proteinuria. Heavy proteinuria results in 
downstream injury to the tubulointerstitium. Therefore, it is thought that proteinuria is a link 
between glomerulus and tubulointerstitium (Remuzzi et al. 1998, Glassock In: Primer on 
Kidney Diseases 2005, Harris et al. 2006, Shankland 2006, LeHir et al. 2007). Proteinuria is 
not only a sign of kidney disorders, but also a major factor leading to CKD. 
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Tubular proteinuria is due to impaired renal tubule function, resulting in lower absorption of 
filtered low molecular weight proteins or increased excretion of proteins by damaged tubules. 
Glomerular and tubular proteinuria can coexist, especially when tubulointerstitial injury 
complicates the picture of a primary glomerular disease. Isolated tubular proteinuria is usually 
the result of a hereditary or acquired defect in proximal tubule function (e.g. Dent’s disease 
and Lowes syndrome) (Bockenhauer et al. 2008, Bökenkamp et al. 2009, Gupta et al. 2010). 
The amount of protein excerted is usually modest in tubular proteinuria, normally in the range 
of 200-2000 mg/day (In: Primer on Kidney Diseases 2005).    
              
2.2. Podocytes in glomerular injury 
 
The classification of podocyte injury may be divided into genetic (mutations in podocyte 
genes such as nephrin, -actinin-4 and podocin) and acquired (immune-, and non-immune 
mediated) causes. The response of podocytes to injury is complex and involves numerous 
processes. Podocyte injury is a key initial step that triggers the pathological sequence of 
events leading to progressive filtration barrier failure, presenting as nephrotic or non-
nephrotic proteinuria, glomerulosclerosis and eventually as renal failure (Kerjaschki 2001, 
Mundel et al. 2002, Pollak 2002, Katsuhiko et al. 2003, Pavenstadt et al. 2003).  
 
The change in podocyte shape called effacement is believed to be a stereotypical reaction of 
podocytes to injury. Farquhar et al. 1957 was the first to describe extensive foot process 
effacement in biopsies of patients with nephrotic syndrome. Foot process effacement consists 
of gradual simplification of the inter-digitating foot process pattern, resulting in the formation 
of a cell that looks flat and elongated and giving the appearance of a continuous cytoplasmic 
sheet covering the GBM (Figure 8) (Drumond et al. 1994). Mutations and abnormalities in the 
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SD proteins in human podocytes (such as nephrin and podocin) and mouse podocytes (such as 
FAT-1- and Neph1) are associated with the rearrangement of the podocyte actin cytoskeleton, 
the effacement of foot processes and proteinuria (Kestilä et al. 1998, Boute et al. 2000, 
Tryggvason 1999, Tryggvason et al. 2006, Donoviel et al. 2001, Inoue et al. 2001). There are 
different theories about the relationship between podocyte effacement and proteinuria. 
According to one view, the effacement itself is sufficient to cause proteinuria, while others 
suggest that effacement is the final common pathway to abnormalities/injuries in podocytes 
and does not cause proteinuria. Effacement and proteinuria are also hypothesized to occur 
independently from each other (Patrakka et al. 2002, Kalluri 2006, Shankland 2006).  
 
 
 
Figure 8. Glomerular filtration barrier. (A) Glomerular filtration barrier and foot processes in 
healthy glomeruli, (B) Foot process effacement and proteinuria in injured glomeruli. Adapted 
from Ronco, J Clin Invest (2007) 117: 2079-2082. Reproduced with permission from the 
copyright holder.                                                                
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Podocytes are specialized cells that have very limited potential for repair. Severely affected 
podocytes by a variety of damaging mechanisms is shown to cause podocyte loss (De Zoysa 
et al. 2005, Shankland 2006, Jefferson et al. 2008). Based on morphological analyses of 
kidneys with focal and segmental glomerulosclerosis (FSGS), Kriz and others have developed 
the widely accepted ―podocyte depletion theory‖. It suggests that in proteinuric kidneys 
apoptosis or detachment of podocytes leads to denuded areas of the GBM, which adhere to 
Bowman’s capsule. It further results in misdirected filtration of urine into the paraglomerular 
and paratubular space, leading finally to nephron loss (Figure 9) (Kriz et al. 1998, Gassler et 
al. 2001, Kriz et al. 2005). ―The depletion theory‖ is supported by studies with experimental 
animal models and with some human disorders (Kriz et al. 1998, Steffes et al. 2001, Lemley 
et al. 2002, White et al. 2004, Kriz et al. 2005,). However, no signs of podocyte depletion 
were recently found in NPHS1 kidneys, speaking against the depletion theory in this disease 
(Lahdenkari et al. 2004).  
   
 
Figure 9. Podocyte depletion theory. (A) Normal glomerulus, (B) Podocyte injury and 
depletion, (C) Bare areas of GBM in sites of podocyte depletion and (D) Attachment of 
parietal epithelial cells to the naked GBM and formation of a segmental lesion and 
misdirected filtration of urine. Modified from the original drawing by W. Kriz. 
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2.3 Mesangial cells in response to injury 
 
2.3.1 Mesangial cell proliferation and transdifferentiation 
 
Proliferation of mesangial cells is a common finding in a number of diseases that can lead to 
end-stage renal failure. A variety of initial insults, which may be metabolic (as in diabetic 
nephropathy), or immunological (as in IgA disease and lupus nephritis), can cause 
uncontrolled mesangial cell proliferation (Smith et al. 2000, Hsu 2001, Kurogi 2003, Cove-
Smith et al. 2008). Mesangial cells proliferate quickly in response to many of these insults 
and are usually the last to return to normal in pathological processes involving glomeruli 
(Schöcklmann et al. 1999, Eddy 2000, Hirschberg 2005). Mesangial cells are thought to 
―trans‖ or ―de‖-differentiate in response to injury from a mature, adult, pericyte-like 
phenotype (the ―mesangiocyte‖) to an embryonic myofibroblast one (the ―mesangioblast‖) 
characterized by proliferation and contraction (El Nahas 2003). Upregulation of -smooth 
muscle actin (SMA) is a typical sign of a phenotypic change in mesangial cells, and it is 
associated with mesangial proliferation (Chebotareva et al. 2002). This mesangioblastic 
phenotype has been described in experimental and clinical nephropathies associated with 
glomerular proliferative and sclerotic changes (Johnson et al. 1992, El Nahas et al. 1997). 
Two types of increased mesangial cell proliferation have been suggested. In ―reconstitutive‖ 
proliferation, mesangiolysis and the loss of mesangial cells is followed by the defective 
repopulation of mesangial cells, leading to hypocellularity and sclerosis. In ―non-
reconstitutive‖ proliferation, mesangial cell activation and hyperplasia occur without prior 
cell loss, resulting in hypercellularity and glomerulosclerosis (Schöcklmann et al. 1999). 
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2.3.2 Extracellular matrix (ECM) accumulation  
 
Changes in the mesangial cell activation status may result in altered extracellular matrix 
(ECM) synthesis (Kriz et al. 1990). Normal mature mesangial cells are capable of 
synthesizing the glomerular ECM, including collagen IV and smaller amounts of laminin, 
fibronectin, tenascin and proteoglycans (Rosenblum 1994). The activated mesangioblasts are 
capable of releasing interstitial collagen types I and III, which are not detected in healthy 
glomeruli (Kelly et al. 2001, Yang et al. 2001). Glomerular matrix metalloproteinases 
(MMPs) and their inhibitors (TIMPs) have an important role in controlling the balance of 
ECM synthesis and degradation in kidney glomeruli (Sterzel et al. 1992, Lenz et al. 2000). 
The role of MMPs and TIMPs in the development of glomerular damage has been studied in a 
variety of experimental conditions. Various forms of glomerular diseases are characterized by 
a profound shift in the balance between matrix synthesis and degradation (Arthur 1998, Lenz 
et al. 2000). 
  
2.3.3 Growth factors related to phenotypic changes in mesangial cells 
  
Control of the biosynthetic activity of mesangial cells with regard to ECM production 
involves various soluble mediators such as Ang II, transforming growth factor-TGF-), 
connective tissue growth factor (CTGF), platelet-derived growth factor-BB (PDGF-BB), 
basic fibroblast growth factor (bFGF), growth hormone (GH) and insulin-like growth factor 
(IGF-1). TGF-, PDGF-BB and bFGF have been recognized to be the main mediators in the 
development of glomerular scarring in experimental and human kidney diseases (Floege et al. 
1992, Blom et al. 2001). TGF is likely to play a predominant role in these diseases, as it 
has both beneficial and detrimental effects on mesangial cells. A downstream mediator of 
TGF-, CTGF, also plays a role in TGF--induced fibril formation (Schnaper et al. 2003, 
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Fogo 2007). While TGF-has an anti-proliferative effect on MCs, PDGF and bFGF are 
regarded as the major mitogens for mesangial cells.  
 
2.4 Role of microvasculature in renal scarring 
 
The renal microvasculature, which is composed of glomerular and peritubular capillary (PTC) 
networks (PTC), is known to be markedly reduced in CKD (Nangaku 2006). This sequential 
organization allows a balance between glomerular filtration and tubular reabsorption. The 
glomerular capillaries are especially vulnerable to injury because they are exposed to high 
intra- and transcapillary pressure even under normal physiological conditions
 
(Hostetter 2003, 
Baylis et al. 1978). The increased intracapillary pressure is suggested to cause mesangial cell 
hypertrophy and matrix expansion, changes in GBM-podocyte interactions, podocyte 
hypertrophy, and eventually apoptosis with podocyte loss and glomerulosclerosis (Segerer et 
al. 2007, Hostetter 2003). Irrespective of the initiating process, a decrease in preglomerular or 
glomerular blood flow is associated with the reduction in PTC blood flow. The injury and loss 
of PTCs result in impairment of oxygen and nutrient delivery to the tubuli and interstitial 
cells, correlating with fibrosis and tubular atrophy (Choi et al. 2000, Eddy 2000, Rabelink et 
al. 2002, Norman et al. 2006). Another consequence of the peritubular circulation being 
downstream of the glomerulus is that inflammatory and profibrotic mediators generated 
within the glomerulus may spill over and activate the endothelium of the peritubular 
microcirculation, thus contributing to the secondary interstitial inflammatory reaction 
(Nangaku 2004).  
 
2.5 Endothelial dysfunction 
 
Endothelial dysfunction is recognized as a key process in many types of acute and chronic 
renal failures. It is known to play a central role in haemolytic uremic syndrome, in various 
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types of glomerulonephritis as well as in hypertension, metabolic syndrome and diabetic 
nephropathy (Molitoris et al. 2004, Johnson et al. 2005, Koc et al. 2005, Noris and Remuzzi 
2005, O`Riordan et al. 2005, Baylis 2006, Nakagawa et al. 2006). Endothelial cells once 
injured transiently loose their mature anticoagulant, anti-inflammatory and anti-proliferative 
phenotype and acquire new procoagulant, proinflammatory and mitogenic characteristics. 
This leads to the release of a wide range of chemokines, cytokines and growth factors that 
attract platelets and inflammatory cells (Savage 1994, El Nahas 2003). Endothelial 
dysfunction may also lead to endothelial cell detachment or death, resulting in the atrophy of 
capillaries (Kang et al. 2002, Kang et al. 2003). The pathophysiology of endothelial 
dysfunction is complex and involves multiple mechanisms. Systemic endothelial dysfunction 
is manifested by increased endothelial permeability, impaired nitric oxide production, 
vasodilatation, oxidative stress, upregulation of adhesion molecules and development of a 
prothrombic phenotype (Endemann et al. 2004). 
 
2.5.1 Nitric oxide deficiency and oxidative stress in endothelial dysfunction 
 
The majority of the studies investigating the mechanisms of endothelial dysfunction in CKD 
have focused on systemic NO deficiency as the principal triggering event leading to 
endothelial dysfunction. The decreased activity of endothelial nitric oxide synthase (eNOS) or 
reduced NO availability of damaged endothelium is an important factor in the loss of 
glomerular endothelial anticoagulant and anti-inflammatory properties (Endemann et al. 
2004, Segal et al. 2006). 
 
Some mechanisms that reduce NO availability in endothelial cells have been proposed. NO 
deficiency may be due to impaired NO production by the endothelium and/or increased 
inactivation of NO by reactive oxygen species (ROS). ROS are known to quench NO with 
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formation peroxynitrite (ONOO
-
) (Schmidt et al. 2000), which is a cytotoxic oxidant, and 
through nitration of proteins will affect protein function and therefore endothelial function. 
The evidence for the involvement of increased oxidative stress in systemic endothelial 
dysfunction is further supported by a direct relationship between endothelium-dependent 
vasodilatation and plasma markers of oxidative stress (Annuk et al. 2001).  
 
A relatively new and attractive mechanism that leads to low NO production is asymmetric 
dimethylarginine (ADMA). It has been proposed that high levels of ADMA may interfere 
with the normal L-arginine-stimulated NO synthesis (Schmidt et al. 2000). Vallance et al. are 
reported elevated plasma levels of endogenous ADMA in dialysed patients, which is a 
competitive inhibitor of constitutively expressed eNOS (Vallance et al. 1992). Thus, while the 
prevailing evidence shows that NO deficiency is an important factor in endothelial 
dysfunction of chronic renal failure, the exact role of kidney-specific mechanisms awaits to be 
further characterization. 
 
Another important cause for endothelial dysfunction in chronic renal failure is believed to be 
excessive oxidative stress. Experimental and clinical studies have indicated that oxidative 
stress is associated with alterations in normal endothelial functions. Oxidative stress-induced 
functional changes are observed in several kidney diseases (Hasdan et al. 2002, Ferraro et al. 
2003). Oxidative stress is defined as an increase in the steady-state levels of ROS and may 
occur as a result of increased free radical generation and/or decreased anti-oxidant defence 
mechanisms. Decreased concentrations of plasma or tissue superoxide dismutase (SOD), 
catalase (CAT), glutathione and ascorbic acid are reported in both clinical and experimental 
diabetes (Giugliano et al. 1996). ROS may also modify endothelial function directly by 
activating several transcription factors, leading to upregulation of adhesion molecules into 
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plateles and leukocytes, or by inducing oxidation of low- density lipoprotein. An increase in 
ROS concentration can also impair nitric oxide production and activity.
 
These findings are 
supported by animal model studies of chronic renal failure and hypertension in which 
enhanced generation of ROS led to reduced NO bioavailability and endothelial dysfunction 
and was prevented by antioxidant pre-treatment (Hasdan et al. 2002, Vaziri et al. 2002).  
 
2.5.2 Upregulation of adhesion and chemoattractant molecules 
 
The upregulation of adhesion molecules, the generation of chemokines, such as macrophage 
chemoattractant peptide-1 (MCP-1), and the production of plasminogen activator inhibitor-1 
(PAI-1) participate in the inflammatory response and the development of endothelial 
dysfunction. The upregulation of vascular cell adhesion molecule-1 (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1) and E-selectin plays an important role in the initiation of the 
vascular inflammatory process. VCAM-1 attracts monocytes and T lymphocytes to the vessel 
wall, which is the first step of the inflammation process (Libby 2002). Increased endothelial 
expression of ICAM-1 is a direct response to oxidant injury (Ichikawa et al. 1997).  
 
2.5.3 Vascular endothelial growth factor (VEGF) 
 
NO deficiency may impair the recovery of glomerular endothelial cells from injury by down-
regulating the expression of angiogenic vascular endothelial growth factor (VEGF) (Kang et 
al. 2002). VEGF is an endothelium-specific growth factor that promotes endothelial cell 
proliferation, differentiation and survival. It mediates endothelium-dependent vasodilatation 
and induces microvascular hyperpermeability. VEGF synthesis is most prominent in 
glomerular podocytes and tubular epithelial cells, while its receptors are mainly found on 
preglomerular, glomerular and peritubular endothelial cells (Schrivers et al. 2004). Following 
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glomerular injury, regeneration of the glomerular capillary endothelium is likely to rely on 
VEGF-mediated angiogenesis (Kang et al. 2003). An imbalance in VEGF expression is 
characteristic of progressive renal diseases. Impaired glomerular endothelial angiogenesis has 
been reported after subtotal nephrectomy and is implicated in the development of 
glomerulosclerosis in remnant kidneys (Kang et al. 2003), whereas elevated levels of 
circulating soluble VEGF receptors are associated with pre-eclampsia (Hayman et al. 1999, 
Davison et al. 2004). In an experimental model of rat crescentic glomerulonephritis, the 
administration of soluble FMS-like tyrosine kinase (sFlt-1), a selective and potent inhibitor of 
VEGF, accelerated proteinuria with massive ascites, glomerulosclerosis and interstitial 
fibrosis, and was associated with loss of nephrin and endothelium (Hara et al. 2006). 
 
2.6 Hypoxia 
 
Hypoxia has long been thought to be a major factor in the progression of CKD, irrespective of 
the underlying cause (Fine et al. 2000, Nangaku 2004, Nangaku 2006). It plays an important 
role in several models of chronic renal failure, such as remnant kidneys (Manotham et al. 
2004), diabetic nephropathy (Reis et al. 2003), folic acid nephropathy (Yuan et al. 2003), 
adriamycin nephrosis (Kariatis et al. 2005) and remnant kidney puromycin aminonucleoside 
(PAN) nephrosis (Tanaka et al. 2004). Tissue hypoxia, as ―renal scarring‖, is associated with 
loss of microvasculature, leading to decreased blood flow and impaired oxygenation in areas 
of fibrosis. Although a total loss of the blood flow supply would clearly render the tissue 
hypoxic, there are other complementary mechanisms by which hypoxia can arise in the 
absence of overt capillary obliteration (Nangaku 2006, Eckardt et al. 2005). These include 
decreased capillary flow, an imbalance in vasoactive factors with an upregulation of 
vasoconstrictors, notably Ang II (Nangaku et al. 2008) and/or a reduced amount of 
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vasodilatory factors, such as NO, as well as increased metabolic demands as a result of 
hyperfiltration by uninjured nephrons and oxidative stress (Norman et al. 2006). 
 
 
2.6.1 Hypoxia-inducible factor (HIF) 
 
Hypoxia is known to regulate the expression of a large number of genes, many of which 
contribute to cell survival and adaptation (Semenza 2003). One of the most important factors 
in cellular response to hypoxia is hypoxia-inducible factor (HIF) (Hofer et al. 2002). HIF 
binds to the hypoxia- responsive element in the cis-regulatory regions of its target genes and 
transcriptionally activates genes encoding proteins that mediate adaptive responses to reduced 
oxygen availability. Under conditions of normal oxygen, the HIF- subunit is hydroxylated 
by specific prolyl-hydroxylases and targeted for rapid proteasomal degradation by the von 
Hippel-Lindau (VHL) tumour suppressor, which is the substrate recognition component of 
E3-ubiquitin ligase. In hypoxic conditions, HIF- is not degraded and translocates to the 
nucleus, where it dimerizes with HIF- to form transcriptionally active HIF (Bernhardt et al. 
2006). There are three known HIF- subunits, HIF-1, HIF-2, and HIF-3(the role of HIF-
3 in hypoxic signalling is unclear). In kidneys, HIF-1 expression is observed in all nephron 
segments, whereas HIF-2 is expressed only in renal endothelial and interstitial cells (Haase 
2006). The list of HIF target genes has grown rapidly and includes genes that have well-
demonstrated relevance to the pathogenesis of acute and chronic kidney disases. These 
include, among others, haemeoxygenase-1, VEGF, PAI-1, TIMP-1 and CTGF (Wenger 2002, 
Higgins et al. 2004). 
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2.6.2 Hypoxia and inflammation 
 
CKD is also associated with an inflammatory response, and it has been suggested that 
persistence of inflammation is an intrinsic component of disease progression (Eddy 2005). 
Hypoxia plays an important role in inflammation by providing a homing signal for 
inflammatory cells (Kong et al. 2004). Macrophages accumulate at sites of vascular 
disruption and respond to the hypoxic environment by activating other inflammatory cells and 
by altering a wide array of genes involved in survival, tissue revascularization and recruitment 
(Kong et al. 2004, Murdoch et al. 2005). Oxygen consumption by macrophages may also 
exacerbate local hypoxia. Where neovascularization restores tissue oxygenation, the 
inflammatory response is terminated, but in the absence of angiogenic repair, chronic hypoxia 
may potentiate an ongoing inflammatory response and fibrosis (Norman et al. 2006).   
 
2.7 Oxidative stress and reactive oxygen species (ROS) 
 
There is a homeostatic balance between formation of reactive oxygen species (ROS) and their 
removal by endogenous antioxidant compounds under normal physiological conditions 
(Gutteridge et al. 1999). In normal circumstances, the kidney generates ROS, including the 
free radical superoxide anion (O2
-
), the non-radical hydrogen peroxide (H2O2), the highly 
reactive hydroxyl free radical (OH) and peroxynitrite (ONOO
-
), which are efficiently 
eliminated by enzymatic superoxide dismutase (SOD), catalase, glutathione peroxidase 
(GPX) and non-enzymatic compounds (glutathione, vitamins C and E) (Araujo et al. 2006). 
Oxidative stress occurs when ROS production overrides the metabolic capacity of the 
antioxidant defence system, often resulting in tissue damage. In renal failure, there are several 
potential sources of ROS, including the mitochondrial respiratory electron transport chain, 
xanthine oxidase activation as a result of ischaemia/reperfusion and endothelial- and 
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neutrophil-associated respiratory burst through activation of nicotinamide adenine 
dinucleotide phosphate (NADPH)-oxidase (Macdonald et al. 2003, Jaber et al.  2005). 
 
2.7.1 NAD(P)H oxidase complex 
 
The NAD(P)H oxidase is an enzyme complex that is responsible for the generation of O2
-
 in 
neutrophils during the respiratory burst. Under normal conditions, the prototypic neutrophil 
NAD(P)H oxidase is dormant in non-activated neutrophils with only two subunits, 
glycoprotein gp91phox (for phagocyte oxidase) and p22phox, comprising the membrane-
bound cytochrome b558. During the respiratory burst and cellular activation the additional 
components p67phox, p47phox, p40phox and Rac1 shift from the cytosol to the membrane 
(Figure 10). These proteins bind to the poly-L-proline-rich domain of p22phox through the 
interaction of the src homology domain-3 (SH3). The SH3-mediated interaction induces the 
combination of p67phox with p47phox. The translocation activates the NAD(P)H oxidase to 
generate large amounts of O2
-
 (Sachse 2007). Although all components of the classical 
neutrophil NAD(P)H oxidase are also found in non-phagocytic cells (e.g. in endothelial cells), 
there are several important structural and functional differences between these two cell types. 
In neutrophils, the NAD(P)H oxidase complex, the gp91phox, is named Nox2, whereas the 
gp91phox isoforms Nox1, Nox3 and Nox5 are expressed in non-phagocytic cells (Krause 
2004, Gill et al. 2006, Guzik et al. 2006).  
 
Nox enzymes play an important role in tissue remodelling and fibrosis as shown by their 
involvement in epithelial-mesenchymal transition (EMT) (Cucoranu et al. 2005, Rhyu et al. 
2005, Djamali et al. 2009). Furthermore, several lines of evidence suggest that Nox proteins 
are involved in the pathogenesis of diabetic, hypertensive and glomerular kidney diseases 
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(Zhan et al. 2004 Asaba et al. 2005, Gorin et al. 2005, Kondo et al. 2006, Modlinger et al. 
2006). 
 
                     
Figure 10. The compounds of NAD(P)H oxidase complex. Non-activated NAD(P)H  oxidase 
consists of two subunits, Nox1-5 and p22phox. During the respiratory burst and cellular 
activation the additional components p67phox, p47phox, p40phox and Rac1 shift from the 
cytosol to the membrane, activating the NAD(P)H oxidase to generate large amounts of O2
-
. 
Adapted from Sachse et al. J Am Soc Nephrol (2007) 18: 2439-2446. Reproduced with 
permission from the copyright holder.                                                                
 
2.7.2 Angiotensin II and ROS formation in renal disease 
 
Angiotensin II (Ang II), synthesized by tubular cells, is an important mediator in renal injuy. 
It is a multifunctional cytokine that exhibits many proinflammatory and non-hemodynamic 
properties such as acting as a growth factor and a profibrogenic cytokine. Ang II also induces 
other growth factors, e.g. TGF-and chemoattractants in the kidney. Ang II is the primary 
effector in many pathophysiological processes, including proteinuria, inflammation and 
fibrosis (Rüster et al. 2006, Wolf 2006).  
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Ang II has an important role in the induction of oxidative stress and the production of ROS. 
Ang II stimulation has been shown to upregulate various NAD(P)H oxidase subunits, 
including Nox1, p47phox, p67phox and p22phox, in various cell types (Lassegue et al. 2001, 
Touyz et al. 2005, Cheng et al. 2006, Hingtgen et al. 2006). The main function of Ang II-
stimulated ROS is the modification of the activity of tyrosine kinases and phosphatases and 
the activation of mitogen-activated protein (MAPK) kinases (p38MAPK, Jun N-terminal 
kinase (JNK), extracellular signal-regulated kinase 5 (ERK5) and the stimulation of 
transcription factors (nuclear factor-B (NF-B), HIF-1, activation protein-1 (AP-1)). ROS 
can also directly change the activity of ion channels and alter the generation of NO by 
uncoupling of endothelial NOS (eNOS) (Sachse et al. 2007). Even though Ang II-induced 
ROS formation has been demonstrated in several experimental studies (Matsuno et al. 2005, 
Thomas et al. 2006), the extrapolation of this concept to the pathophysiology and treatment of 
human renal disease has been problematic. ROS may play a pivotal role in several 
pathophysiological diseases of the kidney and vasculature such as IgA nephropathy, diabetic 
nephropathy, hypertension, acute renal failure and progression of renal disease (Ha et al. 
2008, Harrison et al. 2009, Ohashi et al. 2009). 
 
2.8 Tubular epithelial cell injury 
The downstream position of the tubulus, with respect to the glomerulus, does not only apply 
to the blood flow but also to the ultrafiltrate, which may become another avenue for spreading 
of primarily glomerular disease to the tubulointerstitial compartment. Increased protein 
delivery to the proximal tubule is associated with increased protein reabsorption in the 
proximal tubule (Ruggeneti et al. 2000, Benigni et al. 2001). With the development of 
glomerular disease, the tubular ability to reabsorb protein may be reduced. The increased 
glomerular proteinuria can easily overwhelm the capacity of injured tubular cells to reabsorb 
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the filtered protein load. Increased protein filtration may also have direct toxic effects on 
tubular epithelial cells, induce chemokine and cytokine secretion and result in upregulation of 
adhesion molecules, all contributing to the influx of mononuclear cells. Inflammatory cells, in 
turn, secrete cytokines, which stimulate resident cells and tubular epithelial cells (Kriz et al. 
1998, Nangaku 2004, 2006, Abbate et al. 2006, Segerer et al. 2007, Strutz 2009). 
Epithelial-mesenchymal transition (EMT) is involved in injured epithelial cells and is 
known to play an important role in the progression of fibrosis in the kidney. Tubular EMT is a 
process in which renal tubular cells lose their epithelial phenotype and acquire a 
mesenchymal phenotype. Tubular EMT at the cellular level is a step-wise process involving 
four crucial steps: (1) loss of epithelial adhesion properties, (2) de novo alpha smooth muscle 
actin (SMA) expression and actin reorganization, (3) disruption of tubular basement 
membrane and (4) enhanced cell migration and invasion (Liu 2004). Tubular cells with EMT 
typically express SMA, actin filaments, vimentin, type I collagen, fibroblast-specific protein 
1 (in mice) and a loose epithelial cell marker such as E-cadherin (Iwano 2002). EMT is 
believed to be a major contributor to the pathogenesis of renal fibrosis, as it leads to a 
substantial increase in the number of myofibroblasts and tubular atrophy (Zeisberg et al. 
2004). EMT has been regarded as an important phenomenon for disease progression in animal 
model studies (Ng et al. 1998, Yang et al. 2001, Iwano et al. 2002), in cell culture research 
(Struz et al. 1995, Oldfield et al. 2001, Li et al. 2003) and in some human studies (Nadasdy et 
al. 1994, Jinde et al. 2001, Rastaldi et al. 2002).  
The identification of cubilin and megalin as key components in the reabsorption of albumin 
suggests, that they also play a role in the progression of renal fibrosis. This may occur simply 
by allowing reabsorption of a greater amount of protein in proteinuric states. Cubilin and 
megalin proteins interact with each other and mediate the reabsorption of a large number of 
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filtered proteins, but dysfunction in either protein results in tubular proteinuria (Verroust et al. 
2002). The proteinuria observed in megalin-deficient mice, in dogs lacking functional cubilin 
and in patients with distinct mutations of the cubilin gene supports the importance of these 
receptors in the pathology of renal disease (Christensen et al. 2007). 
 
3. Congenital nephrotic syndrome of the Finnish type (NPHS1, CNF) 
Congenital nephrotic syndromes (CNSs) form a heterogenous group of diseases characterized 
by proteinuria within the first three months of life. The most common type of CNS is the 
congenital nephrotic syndrome of the Finnish type (NPHS1, CNF). NPHS1 is an autosomal 
recessive kidney disorder first described by Hallman and co-workers (1956), and it was the 
first disease of the entity later known as the Finnish disease inheritage. NPHS1 is the best-
characterized type of nephrotic syndrome with typical clinical features and pathological 
findings (Rapola et al. 1984, Rapola 1987, Holmberg et al. 1995). The disease is highly 
enriched in the Finnish population, the incidence being approximately 1/8200 live births 
(Hallman et al. 1956, Norio 1966, Huttunen 1976). Increasing numbers of patients with 
NPHS1 have been reported worldwide among various ethnic groups (Bolk et al. 1999, 
Beltcheva et al. 2001, Gigante et al. 2005, Hinkes et al. 2007, Aya et al. 2009, Ismaili et al. 
2009, Lee et al. 2009, Tikhomirov et al. 2009).  
 
3.1 NPHS1 gene and nephrin 
 
 NPHS1 is caused by mutations in the NPHS1 gene. The gene has a size of 26 kb, and it is 
located on chromosome 19q13.1. It contains 29 exons and encodes for the nephrin protein. 
There are two main mutations that account for 97% of NPHS1 cases in Finland: Fin-major 
and Fin-minor (Kestilä et al. 1998) (Figure 11). Sixty percent of Finnish patients are 
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homozygous for the Fin-major mutation, which is a two base-pair deletion (121-122 del CT) 
in exon 2, resulting in a frameshift and an early stop codon. The gene product is a truncated 
protein consisting of only 90 amino acids. The Fin-minor mutation is a nonsense mutation 
(3325 C->T) in exon 26, where a substitution of one nucleotide leads to stop a codon and 
consequently to a truncated protein of 1109 amino acids. In addition to Fin-major and Fin-
minor, a few missense mutations in Finnish patients have been found (Lenkkeri et al. 1999). 
 
 The Fin-major and Fin-minor mutations are rare outside Finland. In contrast to Finnish 
patients, most non-Finnish patients have ―individual mutations‖. At the moment, 120 different 
mutations in NPHS1 have been described, including deletions and missense mutations. 
NPHS1 mutations are distributed throughout the gene affecting both the extracellular and the 
intracellular domains of nephrin (Heeringa et al. 2008, Hildebrandt et al. 2009). 
 
The essential role of nephrin in formation and function of the SD has also been demonstrated 
by the knock-out (KO) mice studies (Putaala et al. 2001). NPHS1 null mice completely lack 
the SD and develop massive non-selective proteinuria at birth and die within 24 hours. 
 
 
 53 
                  
Figure 11. (A) NPHS1 gene. (B) Nephrin protein and mutations in Finnish patients. Adapted 
from Patrakka et al. Kidney Int (2000) 58: 972-980. Reproduced with permission from the 
copyright holder. 
 
3.2 Clinical features 
 
NPHS1 specifically affects the kidney, and proteinuria begins already in utero and can be 
detected in the first urine samples (Patrakka et al. 2002). The NPHS1 child is often born 
prematurely, and the placenta is disproportionally large for an unknown reason, accounting 
for more than 25% of the child’s birth weight (Patrakka et al. 2000). Nephrotic syndrome 
with heavy proteinuria, hypoproteinemia, edema and secondary manifestations is often 
detected shortly after birth. NPHS1 children are treated intensively with daily albumin 
infusions and a high-calorie diet to compensate for protein losses. After a patient reaches a 
weight of 7 kg, a bilateral nephrectomy is performed and dialysis is initiated to further 
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improve the nutritional stage. Kidney transplantation, the only curative treatment for NPHS1, 
is usually performed at the age of 1-2 years (Jalanko 2009). 
 
In light microscopy, the histology of NPHS1 kidneys is shown to range from nearly normal to 
severely damaged. In addition to glomerular sclerosis, the histological findings of affected 
NPHS1 kidneys include interstitial fibrosis and inflammation, arterial wall thickening, tubular 
atrophy and dilatation and accumulation of proteinaceous material into tubular lumen 
(Kuusiemi et al 2005). Affected glomeruli are scattered throughout the cortex and fairly 
normal and totally sclerotic glomeruli and tubuli can be seen next to each other. 
 
The podocyte structure is altered in NPHS1 glomeruli. Foot process effacement and fusion are 
the most typical ultrastructural findings in the glomeruli of NPHS1 kidneys (Lahdenkari et al. 
2004). Filamentous SD is not observed in transmission electron microscopy images of 
NPHS1 kidneys (Patrakka et al. 2000). Podocyte cell bodies are prominent and have a 
balloon-like appearance (Lahdenkari et al. 2004). Only one primary foot process has been 
demonstrated to connect the cell body to a flat cytoplasmic sheet without any branching 
(Figure 12). No areas of denuded glomerular basement membrane (GBM) are present 
(Lahdenkari et al. 2004). The podocytes show marked structural and phenotypic changes in 
NPHS1 kidneys: Podocytes are in hypertrophic state with low rate of proliferation. Neither 
podocyte layer hyperplasia nor apoptosis is observed (Kuusniemi et al. 2006).  
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Figure 12. Transmission electron microscopy (TEM) images of the glomerular capillary wall 
in (A) control and (B) NPHS1 kidneys. Effacement and flattening of podocyte foot processes 
was evident in the NPHS1 kidney. Adapted from Lahdenkari et al. J Am Soc Nephrol (2004) 
15: 2611-2618. Reproduced with permission from the copyright holder. 
 
The most constant glomerular finding in NPHS1 kidneys is progressive mesangial sclerosis 
and accumulation of ECM proteins in the mesangium, as reported previously (Rapola et al. 
1971, Kuusniemi et al. 2006) (Figure 13.) The mesangium is shown to be affected in 
practically every glomerulus so that the lesions range from mild widening to total sclerosis.  
 
Tubular dilatation with flattening of epithelial cells is common in NPHS1 kidneys. The 
tubular epithelial cells contain protein- and lipid-rich vesicles. Despite the upregulation of 
mesangial marker vimentin, there is no evidence of epithelial-mesenchymal transition (EMT). 
In overall, the tubular epithelium in NPHS1 kidneys is quite resistant to proteinuria. 
Interstitial fibrosis is evident in the vicinity of glomeruli and sclerotic arteries and around 
degenerating tubuli in NPHS1 kidneys (Kuusniemi et al. 2005). 
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Figure 13. Histology of NPHS1 kidneys. (A) Glomerulosclerosis, tubular dilatation and 
atrophy, arterial wall thickening and inflammation. Glomerulosclerosis with (B) mildly 
damaged and (C) totally sclerotic glomeruli. (D) Close-up of the walls of two adjacent tubules 
showing accumulation of proteinaceous material (black) and occasional lipid droplets (white) 
inside tubular epithelial cells. (E) Silver staining showing intact tubular basement membranes 
in tubuli. Adapted from Kuusniemi et al. Kidney Int (2005) 68: 121-132. Reproduced with 
permission from the copyright holder.                                                                
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AIMS OF THE STUDY 
 
Persistent proteinuria in kidney disease is a major factor leading to end-stage renal failure. 
Understanding of this progressive process is crucial for nephrology. The NPHS1 kidneys show 
heavy proteinuria and fast development of fibrotic scarring. These NPHS1 kidneys, removed in 
infancy, serve as an excellent human material for studies of the pathophysiology of proteinuric 
kidney diseases. The aim of this research was to characterize this process in kidneys with NPHS1. 
Specific aims were as follows: 
 
1. To investigate the cellular and molecular mechanisms affecting the glomerular mesangium 
in NPHS1 kidneys.  
2. To evaluate the structure and the role of glomerular and peritubular capillaries in the 
pathology of NPHS1. 
3. To analyse the role of the RAS system and oxidative stress in NPHS1 kidneys. 
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MATERIALS AND METHODS 
 
The original articles are referenced by Roman numerals in parentheses.  
 
 
1. Kidney tissue samples (I-IV) 
Renal tissue samples were obtained from a total of 44 kidneys, removed from children with NPHS1 
(aged 3-44 months), between 1986 and 2007 as a part of the routine clinical treatment (I-IV). For  
control group 1, we used ten normal adult kidneys (aged 47-58 years) unsuitable for transplantation 
mainly because of vascular abnormalities (I-IV). Control group 2 consisted of biopsies from 14 
children (aged 2-14 years). Ten of these patients suffered from minimal change nephrotic syndrome 
(MCNS), three patients suffered from focal segmental glomerulosclerosis (FSGS), and one patient 
had mesangioproliferative glomerulonephritis (I, III). Porcine kidney samples were obtained from 
two newborns and one six-month-old pig (IV). In addition, renal biopsy samples from seven 
patients with tubulointerstitial nephritis or MCNS (in remission) were used as controls in 
transmission electron microscopy (TEM). The age of the patients at the time of biopsies ranged 
between 1 and 55 years. 
 
2. Immunohistochemistry (I-IV) 
Commercial primary and secondary antibodies were used in immunoperoxidase and 
immunofluorescence stainings as described in detail in the original publications (I-IV). 
 
2.1 Immunoperoxidase staining  
 
Immunoperoxidase stainings were performed using sections of formalin-fixed, paraffin-embedded 
or snap-frozen, acetone-fixed cryosections of kidney tissue samples. Paraffin-embedded tissue 
samples were deparaffinized and the endogenous peroxidase activity was quenched. Microwave 
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treatment in 10 mmol/l citric acid or commercial solution (DAP) was used to improve the antibody 
penetration. Amplification of the primary antibody reaction was achieved by incubating the sections 
with biotinylated secondary antibody or TSA Indirect (tyramide signal amplification-kit). The 
sections were counterstained with haematoxylin. Immunoperoxidase staining of cryosections fixed 
with acetone or 3.5% paraformaldehyde was performed similarly. 
 
 
2.2 Immunofluorescence staining  
 
For the immunofluorescence staining, the cryosections (5 m) of kidney samples were fixed with 
acetone or 3.5% paraformaldehyde, depending on the antibody used. The sections were incubated 
overnight at 4
o
C with antibodies diluted in phosphate-buffered saline (PBS). Fluorophore-
conjugated secondary antibodies were incubated for 1.5 h. All incubations were followed by three 
5-min washes with PBS. Control sections were incubated in PBS instead of a primary antibody. 
 
3. Light microscopy (I-IV) 
The histological lesions in NPHS1 kidneys were evaluated by light microscopy from paraffin-
embedded tissue sections stained with periodic acid silver methenamin (PASM), Herovici and 
haematoxylin and eosin (HE). 
 
Images of the immunohistological stainings were analysed using an NIH ImageJ 1.35p program by 
calculating the area fractions of immunostained components. The proportion of black-to-white 
pixels in the image was calculated as a percentage (%). Haphazardly selected areas from the kidney 
cortex (60-200 visual fields) were evaluated and scored from 0 to 3. 
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4. Transmission electron microscopy (TEM) (II) 
The kidney tissue blocks for TEM were fixed with 2.5% glutaraldehyde and embedded in Epon. 
The samples were processed as previously described (Lahdenkari et al. 2004). Evaluation of the 
endothelial cells was performed with TEM by analysing the structure of endothelial cells and 
calculating the number of fenestrae with a Jeol 1200-EX II microscope. 
 
5. Immunoblotting (I-IV) 
For the Western blotting, isolated glomeruli and kidney cortex samples were homogenized in 
Laemmli buffer. Protein concentration was measured by Lowry assay, after which the proteins were 
separated on a gel (7-12%) and blotted onto a polyvinylidene fluoride (PVDF) membrane. The 
membrane was blocked with 5% non-fat milk in PBS, after which the membrane was stained with a 
primary antibody, followed by a peroxidise-conjugated secondary antibody. Visualization was 
performed using enhanced chemiluminescence. 
 
6. Cytokine array (I, II) 
The antibody array consisted of 50 different human cytokine, chemokine, MMP and TIMP 
antibodies spotted in duplicate onto a membrane (Lin Y et al. 2003). Glomerular extracts were 
homogenized in lysis buffer and centrifuged. Protein concentration was measured by Lowry assay. 
The membranes were incubated with a blocking buffer and glomerular lysate was added to the 
membrane and incubated overnight at 4 
o
C. After washes, the membranes were incubated with 
biotinylated antibody for 2 h, washed and incubated for 1 h with horse-radish peroxidase (HRP)-
conjugated streptavidin. The membranes were developed with the chemiluminescence system. 
Signal intensity was quantified with freeware image analysis software. All values were compared 
with an internal positive control. 
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7. Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labelling 
(TUNEL) (II) 
The apoptosis in glomerular endothelium was analysed by monitoring DNA fragmentation after 
TUNEL staining (Tilly 1994). The samples were also counterstained with haematoxylin and 
observed under light microscope. Cells exhibiting dark brown staining from the colorimetric 
reaction were considered positive for DNA fragmentation. Negative controls, produced by omitting 
the labelling enzyme, yielded no reaction product.  
 
8. Reverse transcription-polymerase chain reaction (RT-PCR) (III, IV) 
Total RNA from cortical tissues of control and NPHS1 patients was isolated and further purified. 
cDNA synthesis was carried out by incubating 2 g of isolated RNA at 37oC for 1 h. The 
synthesized cDNA was subjected to real-time PCR utilizing RT
2
 Real-Time SYBR Green/ROX 
PCR Master Mix. RT
2
 Profiler PCR Arrays were used to profile the expression of 84 genes related 
to endothelial cell biology and oxidative stress. Specific primers were used for the following RT-
PCR reactions: ACE, ACE2, AT1, AT2 and renin receptor. The PCR was amplified for 40 cycles. 
Each PCR reaction was subjected to melting curve analysis. Threshold cycles for each primer were 
analysed separately. The following equation was used to normalize the expression level of a gene of 
interest (GOI) to a housekeeping gene (HKG = -actin) = 2 – [Ct (GOI) – Ct (HKG)] = 2 -Ct. To determine 
the gene expression profile in NPHS1 cortical tissues, the normalized expression of the GOI in the 
experimental sample (Ct expt) was divided by the normalized expression of the same GOI in the 
control sample (Ct control), where Ct = Ct expt – Ct control. Representative data are 
presented in terms of fold mRNA changes of NPHS1 samples compared with control samples.  
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9. Enzyme arrays (IV) 
The catalase array consisting of the spectrophotometric measurement of 10.3 mM H2O2 breakdown 
at 240 nm was performed following the method of Beers and Sizer (1952). Total superoxide 
dismutase activity was determined by the method of McCord and Fridovich (1969). This assay 
depends on SOD activity to inhibit cytochrome c reduction mediated by the O2
2-
 generated from the 
xanthine oxidase system. SOD activity was monitored spectrophotometrically at 560 nm. Lipid 
peroxidation products were quantified by the thiobarbituric acid (TBA) method (Esterbauer et al. 
1990). Absorbance of the organic phase was determined at 532 nm. 1,1,3,3-tetramethoxypropane 
was used as a standard. Values are presented as nmol of thiobarbituric acid reactive substances per 
gram of tissue (TBARS/g). 
 
10. Statistics 
The differences between control and NPHS1 groups were evaluated using unpaired Student’s t-test 
for continuous variables with normal distribution in the analysis of histological lesions in the 
glomeruli and cortex (I-IV). Differences in the expression of various proteins were examined by 
immunohistochemistry or Western blotting (I-IV), the oxidative stress by enzyme activity and lipid 
peroxidation arrays (IV). Differences between two groups in the distribution of continuous variables 
were analysed with the non-parametric Mann-Whitney U-test (I). Non-parametric test was chosen 
because all distributions were not normal.  
 
11. Ethics 
All of the studies were approved by the Ethics Committee of the Hospital for Children and 
Adolescents, University of Helsinki. 
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RESULTS 
We examined the cellular and molecular mechanisms leading to the progression of 
glomerulosclerosis and tubulointerstitial fibrosis in kidneys removed from children with NPHS1. 
We characterized the mesangial changes and evaluated the expression of major molecular factors 
related to glomerular sclerosis. We studied the structural and phenotypic changes of the glomerular 
endothelium and searched for possible signs of injury and observed loss of peritubular capillaries 
(PTCs). The role of oxidative stress in the progression of fibrosis in NPHS1 kidneys was also 
investigated. 
 
1. Glomerular mesangium in NPHS1 kidneys (I) 
 Systematic analysis of over 1770 glomeruli of ten NPHS1 kidneys showed that the progressive 
mesangial expansion was caused by mesangial cell (MC) hyperplasia and increase in the ECM. The 
number of mesangial cells in glomerular cross-sections (GCSs) was increased 10% when mild and 
moderately affected NPHS1 kidneys were compared, 27% when moderately and severely affected 
NPHS1 kidneys were compared and 40% when mildly and severely affected NPHS1 kidneys were 
compared. Despite hyperplasia, very few mitotic cells were observed in the GCSs of NPHS1 
glomeruli (Figure 14A-C). The number of proliferating cells, analyzed by MIB-1 expression, was 
only slightly increased in the mesangium (0.36 per GCS) when compared with controls (0.19 per 
GCS in control group 1 and 0.16 per GCS in control group 2), indicating that the overall 
proliferation rate of MCs was modest in NPHS1 glomeruli.  
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Figure 14. Mesangial (A-B) hyperplasia and (D-F) ECM accumulation are evident in NPHS1 
glomeruli. NPHS1 glomeruli were classified as (A) mild, (B) medium and (C) severe according to 
increasing amount of mesangial hyperplasia. Herovici staining. NPHS1 glomeruli were classified as 
(D) mild, (E) medium and (F) severe according to a larger mesangial matrix area. PASM staining. 
 
 
Expression of the myofibroblast marker SMA was more than twofold higher in NPHS1 glomeruli 
than in control glomeruli (Figures 15A, B and 16). However, mesangial cells showing macrophage-
like phenotypic transformation or smooth muscle cell differentiation were not observed in NPHS1 
glomeruli. The number of CD34+ mesangial cells was modest, speaking against a bone marrow-
related healing process.  
 
.  
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1.1 Accumulation of ECM proteins (I) 
 
Several ECM proteins accumulated in the mesangium of NPHS1 glomeruli. Interestingly, the 
increase of ECM was mainly due to an accumulation of collagen IV, normally present in ECM 
(Figures 15C, D and 16). The expression of fibronectin and tenascin was similar in both NPHS1 
and control glomeruli. Surprisingly, the expression of collagen I, a major factor in 
glomerulosclerosis, was very low in the mesangium of NPHS1 glomeruli (Figures 15E, F and 16). 
Neither dissolution of the mesangial matrix (mesangiolysis) nor Kimmelstiel-Wilson nodules were 
observed in glomeruli of NPHS1 kidneys. 
                                     
Figure 15. Expression of myofibroblast marker SMA was significantly upregulated in the 
mesangium of (A) NPHS1 glomeruli relative to the mesangium of (B) control glomeruli. Collagen 
IV mostly accounted for the ECM increase in the mesangium of (C) NPHS1 glomeruli, while in the 
mesangium of (D) control glomeruli collagen IV was observed only in the basement membrane. 
Collagen I expression was very low in the mesangium of (E) NPHS1 and (F) control glomeruli.  
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Figure 16. Expression SMA and markers of extracellular matrix accumulation (ECM) in the 
mesangium of NPHS1 and control glomeruli. The expression of immunoperoxidase staining is 
scored from 0 to 3 (mean + SD). *P<0.05, when compared with control group 1, **P<0.05, when 
compared with control groups 1 and 2. 
 
 
The expression profiles of MMPs and TIMPs in glomerular extracts were analyzed by antibody-
based screening array. The expression of MMPs -2 and -9 was slightly upregulated in NPHS1 
glomeruli, whereas TIMP-1 and TIMP-2 levels were quite similar in both NPHS1 and control 
glomeruli.  
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1.2 Expression of profibrotic mediators related to mesangial cells (I) 
 
The expression of profibrotic TGF- the most important mediator controlling the MC functions, 
and its downstream mediator, CTGF, was slightly upregulated in NPHS1 kidneys (Figure 17). The 
expression of pleiotropic cytokine OPN was significantly upregulated in NPHS1 kidneys. 
Downstream signalling of TGF- was studied by analysing the phosphorylation of TGF- receptor 
II (TGF-RII), Smad2 and Smad3 in glomerular extracts of NPHS1 and control kidneys. The 
expression of these signalling components was increased more than twofold in NPHS1 glomeruli, 
when compared with controls. The expression levels of PDGF-BB, a major MC mitogen, and its 
receptors PDGFR and PDGFR were quite similar in the glomeruli of NPHS1 and control 
kidneys. 
 
                              
Figure 17. Expressions of soluble mediators in the mesangium of NPHS1 and glomeruli. 
Immunoperoxidase stainings; the area fraction (%) of the expression (mean + SD). **P<0.05.  
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2. Glomerular capillaries and endothelial cells in NPHS1 kidneys (II) 
 
Light microscopic analysis of NPHS1 kidneys showed that capillary obliteration was evident in 
practically all glomeruli. Marked changes in the capillaries could already be seen in glomeruli with 
mild mesangial changes. The average diameter of the capillary cross-section in mildly affected 
glomeruli was 20% and in severely affected glomeruli 36% shorter than in controls. Analysis of 
endothelial cell marker CD31 expression indicated that capillary lumens were narrowed, and the 
total endothelial surface area was decreased by 60% in NPHS1 glomeruli (Figure 18A, B).  
 
Electron microscopy studies revealed that the overall structure of endothelial cells and their 
adherence to GBM were quite well preserved in NPHS1 kidneys. Detachment of endothelial cells 
from the GBM was not seen. The endothelium was mostly attenuated and showed regular fenestrae 
resembling the endothelium in control kidneys. However, local lesions, such as diffuse oedema and 
numerous blebs (endotheliosis), were evident in the capillary cross-sections of NPHS1 glomeruli 
(Figure 18C, D). On average, approximately 5 blebs per GCS were observed in NPHS1 kidneys (1 
bleb per GCS in control). The bleb size varied, but no total obstruction of capillary lumens was 
detected.  
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Figure 18. Glomerular capillaries in (A) NPHS1 and (B) control kidneys. Analysis of endothelial 
cell marker CD31 expression showed narrowing of capillaries and a decrease in the total endothelial 
cell surface area in NPHS1 glomeruli compared with controls. Glomerular capillary cross-sections 
from (C) an NPHS1 patient showed numerous endothelial blebs (arrows), which were not seen in 
capillary cross-sections of (D) control kidneys.  
 
The number of proliferating cells, analysed by mindbomb homologue 1 (MIB-1) expression, was 
slightly increased in the NPHS1 glomerular endothelium as compared with controls. Apoptosis was 
not prominent, since TUNEL-positive intracapillary cells were not found. The low levels of the pro-
coagulant von Willebrand factor (vWF) and the low numbers of fibrin depositions indicated that the 
glomerular capillaries of NPHS1 kidneys did not suffer from thrombosis. 
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3. Peritubular capillaries (PTC) in NPHS1 kidneys (III) 
The density of PTCs was reduced by approximately 25% and the capillary lumen was narrowed in 
NPHS1 kidneys (Figure 19A, B). The loss of PTCs was clearly associated with the development of 
interstitial fibrosis (collagen I expression) and the appearance of myofibroblasts (SMA 
expression) (Figure 19C, D). The number of PTCs was diminished and peritubular space was 
narrowed also in the areas with well-preserved histology. The endothelial surface area of PTCs was 
diminished by 14%. Direct microscopy and immunohistochemistry studies using antibodies against 
prothrombic vWF and the platelet marker CD61 did not indicate capillary thrombosis in the PTCs 
of NPHS1 kidneys. 
 
                            
 
Figure 19. Peritubular capillaries in (A) NPHS1 and (B) control kidneys visualized by staining with 
CD31 antibody. The reduction of PTC density in NPHS1 kidneys was associated with strong 
expression of (C) collagen I and (D) SMA. 
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4. Molecular mediators and capillary changes (II, III) 
To study signs of endothelial injury and clarify whether vascular endothelium might contribute to 
mesangial expansion and glomerulosclerosis in NPHS1 kidneys, we evaluated the expression of 
several chemokines, cytokines, endothelial adhesion molecules and their ligands. The expression of 
ICAM-1 and several chemoattractants, such as CCL5 (Regulated upon Activation, Normal T-cell 
Expressed, and Secreted, RANTES), CXCL7 (neutrophil-activating peptide 2, NAP-2) and CCL7 
(macrophage chemotactic protein-3, MCP-3) were upregulated in NPHS1 glomeruli compared with 
control kidneys (Figure 20). Intercellular adhesion molecule-1 (ICAM-1), leukocyte function 
antigen-1 (LFA-1) and P-selectin ligand-1 (PSGL-1) were also more prevalent in the glomeruli of 
NPHS1 kidneys (Figure 21). Other adhesion molecules, such as vascular cell adhesion molecule-1 
(VCAM-1), E-selectin and P-selectin, were not upregulated in glomerular endothelial cells of 
NPHS1 kidneys. 
      
Figure 20. Antibody array analysis of glomerular cytokine and chemokine expression. Data are 
presented as mean + SD. *P=0.05, **P<0.01. 
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Figure 21. Expression of endothelial adhesion molecules and their ligands in NPHS1 and control 
glomeruli. (A) The expression of ICAM-1 and VCAM-1 and (B) PSGL-1 and LFA-1 was analysed 
in the glomeruli of NPHS1 and control kidneys by using immunohistochemistry. Data are presented 
as mean + SD. *P<0.01. 
 
 
The overall expression of adhesion molecules in PTCs of NPHS1 kidneys was quite moderate. 
ICAM-1 expression was slightly increased in PTCs of NPHS1 kidneys when compared with 
controls (Figure 22). The expression of LFA-1 (a ligand for ICAM-1) and PSGL-1 was also 
upregulated. Surprisingly, the expression of the key initiators of the vascular inflammatory process, 
VCAM-1 and E-selectin, was observed to be weak in PTCs of NPHS1 kidneys.  
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Figure 22. Expression of adhesion molecules and their ligands in the peritubular space of NPHS1 
kidneys. The expression levels were analysed in NPHS1 and control kidneys by using 
immunohistochemistry. Data are presented as mean + SD. **P<0.01, when compared with control 
group 1. 
 
One of the most important markers for the cellular response to hypoxia is the expression of HIF. 
HIF-1 expression was significantly upregulated in the glomerular capillaries, indicating the 
presence of hypoxia. The expression of VEGF was slightly upregulated in NPHS1 glomeruli as 
compared with controls, which is in accordance with the well-preserved structure of the 
endothelium. Hypoxia was also evident in PTCs of NPHS1 kidneys. HIF-1 was detected around 
tubuli showing nuclear staining, and its expression was more than twofold higher in NPHS1 
kidneys as compared with controls. VEGF expression was not observed in PTCs of NPHS1 
kidneys, but it was mostly expressed in tubuli, in which diffuse cytoplasmic or apical expression 
was observed. The mRNA levels of VEGF-related molecules were similar in control and NPHS1 
kidneys.  
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5. Renin-angiotensin system (RAS) and oxidative stress in NPHS1 kidneys (IV) 
 
 The renin-angiotensin system (RAS) plays a pivotal role in regulating physiological and 
pathophysiological processes in the kidney (Sachse et al. 2007). Ang II is known to induce the 
production of reactive oxygen species (ROS), especially through the NAD(P)H pathway. Based on 
this, we examined localization and expression levels of RAS and NAD(P)H-related molecules in 
NPHS1 kidneys. Ang II, angiotensin-converting enzyme (ACE) and angiotensin-converting enzyme 
2 (ACE2) were highly expressed in both NPHS1 and control kidneys. They were predominantly 
localized in the proximal tubular brush border. Low expression of ACE and ACE2 was detected in 
glomerular visceral and parietal epithelial cells. Ang II receptor 1 (AT1) was present in glomerular 
mesangium, interstitial cells and proximal tubuli, while Ang II receptor 2 (AT2) was localized only 
in tubuli in both control and NPHS1 kidneys. Ang II expression was nearly twofold higher in 
NPHS1 kidneys than in control kidneys. The protein expressions of ACE (0.8-fold), ACE2 (1.2-
fold), AT1 (1.1-fold) and AT2 (1.3-fold) were highly similar in the NPHS1 and control kidneys 
(Figure 23). The relative mRNA levels were higher for ACE2 (9.3-fold), ACE (8.1-fold), AT2 (7.1-
fold) and AT1 (5.3-fold) when compared with control kidneys. 
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Figure 23. Ang II expression was upregulated in NPHS1 kidneys, whereas the expressions of ACE, 
ACE2, AT1 and AT2 were nearly equal in both NPHS1 and control kidneys. The expression levels 
were analysed in NPHS1 and control kidneys by using Western blotting. Data are presented as 
mean + SD. 
 
 
5.1 Oxidants and antioxidant defence in NPHS1 kidneys (IV) 
 
A major source for renal ROS is a family of non-phagocytic NAD(P)H oxidases, including Nox2, 
Nox1 and Nox4. Interaction of the Nox proteins with p22phox is required for the formation of  
functionally active NAD(P)H oxidase. p22phox expression was very low in control kidneys, but the 
interstitial expression of p22phox was 10-fold upregulated in NPHS1 kidneys (Figure 24). p22phox 
was mainly localized within inflammatory cells, and the number of p22phox-expressing glomerular 
and tubular cells was low. Immunohistochemistry for p22phox revealed coexpression of Ang II and 
NAD(P)H  in a few foci of inflammatory cells, but not in tubular cells, suggesting that Ang II is not 
involved in the activation of p22phox expression in NPHS1 kidneys. p22phox was not expressed in 
endothelial cells or tubular cells.  Interestingly, p22phox showed partial colocalization with 
myeloperoxidase (MPO), a neutrophilic granulocyte marker, and CD68, a monocyte/macrophage 
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marker in NPHS1 kidneys, but not in control kidneys. These data suggest that granulocytes, 
monocytes and macrophages may be the inflammatory cell types that produce ROS in NPHS1 
kidneys. 
 
 
Figure 24. Expression of p22phox in the cortex of (A) NPHS1 and (B) control kidneys. (C) The 
expression of p22phox was markedly higher in NPHS1 kidneys than in control kidneys. *P<0.05. 
 
 
The activity of lipid peroxidation, determined by the thiobarbituric acid (TBA) method, was 1.8-
fold higher in the kidney cortex of NPHS1 patients than in the human control and 15.5-fold higher 
than in porcine control. These data are in line with our mRNA analysis showing upregulation of 
molecules, such as alipoprotein, aldehyde oxidase 1 (AOX1) and arachidonate 5-lipoxygenate 
(ALOX5), which are involved in lipid peroxidation and hyperlipidaemia.  
 
The total superoxidase dismutase (SOD) and catalase (CAT) enzyme activities were lower in 
NPHS1 kidneys. In NPHS1 kidneys, the SOD enzyme activity (47.0 U/mg) was decreased by 32% 
compared with human control kidneys (69.5 U/mg) and by 51% when compared with porcine 
control kidneys (95.8 U/mg). The CAT enzyme activity (16.5 U/mg) was decreased by 14% in the 
NPHS1 kidneys compared with human control kidneys (19.1 U/mg) and by 45% compared with 
porcine control kidneys (30.0 U/mg) (Figure 25).  
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Figure 25. (A) The concentration of lipid peroxidation products was almost twofold higher in 
NPHS1 kidneys than in human control and porcine control kidneys. (B) SOD enzyme activity was 
reduced by 32% in NPHS1 kidneys, compared with human control kidneys, and by 51% when 
compared with porcine control kidneys. (C) CAT enzyme activity was downregulated by 14% in the 
NPHS1 kidneys compared with human control kidneys and by 45% compared with porcine control 
kidneys. Data are presented as mean + SD.  
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DISCUSSION 
 
Constant, heavy proteinuria in NPHS1 kidneys inevitably causes glomerular sclerosis and 
destruction of the nephrons. Podocytes obviously play a major role both in protein leakage and in 
triggering the sclerotic process. However, previous results have indicated that podocyte injury alone 
is insufficient to explain the nephron destruction; rather, a complex interplay between different cell 
types in the nephron, i.e. podocytes, mesangial cells and endothelial cells, apparently has an 
important role in the disease progression (Lahdenkari et al. 2004, Kuusniemi et al. 2006). 
Therefore, the key mediators and cellular events explaining the rapid nephron destruction and 
tubulointerstitial lesions in NPHS1 kidneys need to be identified. NPHS1 kidneys serve as an 
excellent module to study the impact of proteinuria on the progression of chronic kidney disorders. 
Understanding this process is crucial for the development of medical drugs that could halt the 
fibrotic process. So far, the only drugs used for these purposes are inhibitors of the RAS system. 
Studies on the molecular pathways leading to end-stage renal failure will hopefully help in future 
research on drug desing. 
 
We observed that progressive mesangial expansion in NPHS1 kidneys was caused by mesangial 
cell proliferation and accumulation of ECM proteins. However, a few changes in the MC phenotype 
of the ECM composition were observed. We demonstrated that glomerular capillaries were 
involved in glomerular scarring by showing endothelial blebbing. The endothelial cells, however, 
showed only a few signs of injury. We also observed that narrowing and hypoperfusion of 
glomerular and peritubular capillaries caused by rarefaction of the capillaries may play an important 
role in the rapid progression of fibrosis in NPHS1 kidneys. The mRNA transcript levels of many 
RAS-related molecules were upregulated in NPHS1 kidneys. The expression of angiotensin II (Ang 
II) was also markedly upregulated at the protein level. Oxidation of polysaturated fatty acids and the 
reduction in antioxidant enzyme activities were observed in tissue homogenates of NPHS1 kidneys. 
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In addition, a significant elevation in the expression of p22phox suggested that NAP(D)H oxidase 
was upregulated in the NPHS1 kidneys.  
 
A major limitation in our study was the unavailability of human control samples. It was impossible 
to obtain normal age-matched kidney material (not showing dysplasia or cellular damage caused by 
cytotoxic drugs). Tissue samples from adult kidneys (unsuitable for transplantation mainly because 
of vascular abnormalities) with normal histology and function and biopsies from children (aged 2-
14 years) who suffered from mostly minimal change nephrotic syndrome were used as controls. 
Therefore, caution is warranted in the interpretation of the results dealing with the expression levels 
of some soluble mediators. Most of the data on NPHS1 kidneys presented is, however, valid 
without optimal controls. This is especially the case with the histological findings and the 
expression of many markers. The methodological limitation is that the analysis of kidney samples 
stained by immunohistochemistry is not highly quantitative. Even though NPHS1 kidneys serve as 
an excellent human material to study the pathology of the disease, they did not enable us to follow 
the progression of the disease in patients.  
 
1. Mesangial alterations in NPHS1 kidneys (I) 
1.1 Mesangial cell proliferation and hyperplasia (I) 
 
Mesangial sclerosis was manifested in NPHS1 glomeruli as a proliferation of MCs. This 
observation explains most of the mesangial expansion seen in the glomerular cross-sections, 
especially in the early stages of disease progression. However, the very low number of mitotic cells 
and the low expression of proliferation marker Ki-67 indicated that the proliferation rate of MCs 
was modest. These were supported by the observation that the expression levels of PDGF-BB, the 
major MC mitogen, and its receptors PDGFR and PDGF were similar in both NPSH1 and 
control kidneys. 
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The mesangium represents the core of the glomerulus from a structural and functional point of view 
and is therefore a common and important site of injury in several glomerular disorders, such as 
diabetic nephropathy, light chain deposition diseases and AL-amyloidosis (Zhu et al. 1995, Mason 
et al. 2003, Teng et al. 2004). Regardless of the source of injury, an imbalance in the control of 
mesangial cell proliferation appears to play a direct role in the degree of progressive renal injury 
and glomerulosclerosis. Two types of increased MC proliferation have been suggested 
(Schöcklmann et al. 1999). In ―reconstitutive‖ proliferation, mesangiolysis and the loss of 
mesangial cells are followed by the defective repopulation of mesangial cells, leading to increased 
mesangial cell size (hypertrophy) and sclerosis (in diabetic nephropathy). In ―non-reconstitutive‖ 
proliferation, there is mesangial cell activation and hyperplasia without prior cell loss, resulting in 
hypercellularity and glomerulosclerosis. In NPHS1 kidneys, the MC proliferation was evident in 
practically all glomeruli and represented the ―non-reconstitutive‖ type. 
 
Persistent MC hyperplasia caused by repetitive or continuous injury is thought to precede and lead 
to irreversible glomerular scarring and the loss of renal function (Johnson et al. 1992, El Nahas 
2003, Cove-Smith et al. 2008). However, as in regular wound healing, the increase in MC 
proliferation most probably reflects a physiological response required for glomerular reconstitution 
and renal tissue repair. This theory is supported by evidence from human glomerular diseases such 
as poststreptococcal glomerulonephritis and lupus nephritis. In these diseases, the expanded 
mesangium caused by MC hyperplasia was completely reconciled after the inflammation was 
subsided (Schöcklmann et al. 1999, Kurogi et al. 2003).  
 
Uncontrolled MC proliferation is known to precede and cause an increase in ECM accumulation, 
which was also evident in the mesangium of NPHS1 glomeruli. The ECM accumulation in NPHS1 
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glomeruli was mainly due to an increased expression of collagen IV, which is the main structural 
component of the normal mesangium. The absence of collagen I in mesangium was surprising since 
the switch from collagen IV to collagens I and III has been shown to be a major event in the 
progression of glomerulosclerosis (El Nahas 2003, Herrera 2006). Interestingly, upregulation of 
other ECM glycoproteins, such as fibronectin or tenascin, was not observed in the mesangium of 
NPHS1 glomeruli. The results show that significant mesangium expansion associated with capillary 
obliteration can occur without significant qualitative cellular or molecular changes in the 
mesangium.  
 
1.2 ECM accumulation and the expression of soluble mediators (I) 
 
The production of ECM by mesangial cells is primarily controlled by soluble mediators such as 
interleukin-1 (IL-1), PDGF, TGF-, CTGF, bFGF and Ang II (Herrera 2006, Cove-Smith et al. 
2008).  The expression of TGF- and its downstream regulator CTGF was upregulated in NPHS1 
kidneys, suggesting that they may have an important role in ECM of NPHS1 glomeruli. The role of 
TGF- as a key mediator controlling mesangial cell function has been suggested by numerous in 
vitro and in vivo studies. TGF- is known to induce the synthesis of both normal ECM and fibrillar 
collagen by mesangial cells (Imai et al. 1994, Kitamura et al. 1998, Mason et al. 2003, Schnaper et 
al. 2003, Teng et al. 2004,). On the other hand, it is an anti-mitotic factor for MCs. It activates 
intracellular signalling pathways involving a range of kinases and intracellular proteins called 
Smads (Derynck et al. 2003, Leask et al. 2004). In our study, we observed that phosphorylated 
forms of TGF-RII, Smad2 and Smad3 were clearly upregulated in NPHS1 kidneys, indicating the 
activation of the Smad pathway in NPHS1 kidneys.  TGF- is also known to induce synthesis of 
SMA, and transdifferentiation of MCs into myofibroblasts. This was also the case in MCs of 
NPHS1 glomeruli, which strongly expressed SMA, indicating myofibroblast transformation. In 
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addition to increased TGF- and CTGF expression, we observed an upregulation of osteopontin 
expression in glomerular podocytes. This was an interesting finding since osteopontin levels have 
been shown to correlate with mesangial expansion and albuminuria in various diabetic nephropathy 
models (Lorenzen et al. 2008).  One may speculate that this could be the link between podocytes 
and mesangium in NPHS1 glomeruli.  
  
In the healthy glomerulus, components of the ECM are synthesized and degraded in a balanced 
manner, maintaining the quantity and quality of the ECM. Many diseases have been associated with 
an imbalance in ECM synthesis and degradation, which may result in an accumulation of ECM 
molecules (Lenz et al. 2000). TGF- is known to suppress the expression of ECM-degrading 
proteases (MMPs) and increase the synthesis of ECM protease inhibitors (TIMPs) (Ahmed et al. 
2007). However, in NPHS1 glomeruli the major glomerular proteases, MMP-2 and MMP-9, were 
moderately upregulated, whereas their inhibitors, TIMP-1 and TIMP-2, were normally expressed. 
 
The mesangial sclerosis in NPHS1 glomeruli is possibly triggered by podocyte damage, which has 
been observed in several congenital disorders (Schlöndorff et al. 2009). The findings are also 
supported by animal model studies showing that direct damage to mesangium does not result in the 
development of total glomerulosclerosis (Mauer et al. 1972, Ichikawa et al. 2005). Some degree of 
mesangial sclerosis is a common finding in all known podocyte gene defects that lead to 
proteinuria. In NPHS1 kidneys, podocyte damage seems to induce a mesangial response that is 
powerful enough to completely destroy the glomerulus. There are several hypotheses concerning 
how podocytes and MCs interact in NPHS1 glomeruli. According to one hypothesis, the potential 
interaction may occur via soluble mediators, produced during glomerular injury (Banas et al. 2002). 
According to other hypothesis, MCs may respond directly to abnormal glomerular flow and plasma 
content (low albumin, high lipids) by generating soluble factors and ECM proteins as well as by 
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activating intracellular signalling pathways (Schlöndorff et al. 2009). Plasma in NPHS1 patients is 
highly lipemic and hypoproteinaemia, which may directly affect MCs. It is clear that more studies 
on signalling processes in MCs are needed. 
 
2. Changes in the microvasculature of NPHS1 nephrons (II, III) 
2.1 Endothelial lesions in glomerular capillaries (II) 
 
In the context of our study, it is useful to distinguish endocapillary (glomerular capillaries and 
mesangium) and extracapillary (podocytes, Bowman’s space and Bowman’s capsule separated from 
the endocapillary compartment by the GBM) injuries (Kriz 1998). In experimental 
glomerulopathies, such as Thy-1-mediated nephropathy (Johnson 1994) or Masugi nephritis (Kühn 
et al. 1977, Shirato et al. 1996), the most common endocapillary injury is mesangiolysis with 
various degrees of endothelial involvement. Mesangial expansion and obliteration of capillaries are 
evident in NPHS1 glomeruli, which prompted us to more thoroughly study glomerular capillaries 
and endothelial cells.  
 
Ultrastructural analysis revealed that the overall structure of endothelial cells was quite well 
preserved in NPHS1 kidneys. However, local lesions, such as diffuse oedema and numerous blebs 
(filled with cell organelles), were observed in the capillary cross-sections of NPHS1 glomeruli. This 
phenomenon is called endotheliosis, and it is known to be a pre-eclampsia-specific disorder and 
only occasionally associated with other proteinuric syndromes (Subramanya et al. 2005, Stillman et 
al. 2007).  Endotheliosis is characterized by endothelial swelling, with a loss of fenestrae and 
narrowing or occlusion of the capillary lumens (Spargo 1976). In pre-eclampsia, it is believed to be 
caused by circulating molecules (sFlt1, soluble-endoglin (s-endoglin)) that inhibit the action of 
VEGF and TGF-(Carty et al. 2008). However, diffuse oedema, which causes obliteration of the 
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pores and formation of large loose structureless blebs, has also been reported as a common response 
of glomerular endothelial cells to injury (Churg et al. 1962). 
 
Surprisingly, the fenestrations of endothelial cells in NPHS1 kidneys were regular, resembling the 
endothelium in control kidneys. The maintenance of the glomerular endothelium and fenestrations 
is largely dependent on the VEGF produced by podocytes (Schrijvers et al. 2004). The podocyte 
damage in NPHS1 kidneys did not seem to affect their ability to produce VEGF, which may be 
important in maintaining the structure and function of the endothelium in NPHS1 glomeruli 
(Eremina et al. 2004, Eremina et al. 2006, Eremina et al. 2007, Quaggin et al. 2008). 
 
Endothelial cell injury may induce considerable phenotypic changes such as cell proliferation, 
hypertrophy and apoptosis (Shankland 1999). Early proliferative response of the endothelium 
followed by unchecked apoptosis has been reported as a common finding in progressive 
glomerulonephritis (Shimizu et al. 1997) and a remnant kidney model (Kitamura et al. 1998). 
Interestingly, the intracapillary cells in NPHS1 kidneys showed little proliferative or apoptotic 
activity, speaking against phenotypic alterations.  
 
Thrombotic microangiopathies, such as haemolytic uremic syndrome (HUS) are characterized by 
the involvement of widespread occlusive microvascular thromboses, resulting in thrombocytopenia, 
microangiopathic haemolytic anaemia and variable signs and symptoms of end-organ ischaemia 
(Furlan et al. 2000). This was, however, not the case with NPHS1 glomeruli because neither 
endothelial cell activation nor development of a prothrombotic state was observed in the glomerular 
capillaries.  However, the abundant expression of HIF-1 in the glomeruli of NPHS1 kidneys 
indicated some degree of glomerular hypoxia. Capillary obliteration and the reduction in the 
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diameter of capillary cross-sections indicated that capillary blood flow was slowed down. These 
observations also suggest the presence of hypoxia in the glomeruli of NPHS1 kidneys.  
 
The upregulation of adhesion molecules and the generation of chemokines are known to participate 
in the inflammatory response contributing to a prothrombic state. To search for signs of the 
endothelial injury, we studied endothelial expression of leukocyte adhesion proteins in NPHS1 
glomeruli. The expression of ICAM-1 and several chemoattractants was upregulated. However, 
endothelial cells showed only little expression of VCAM-1, P- selectin and E-selectin, which have 
been reported to be the key initiators of the vascular inflammatory process (Libby 2002). The 
number of leukocytes in mesangium was also very low in NPHS1 kidneys. These data are in 
agreement with previous data showing only a few mononuclear and polymorphonuclear cells in the 
mesangial area (Kuusniemi et al. 2006).  
 
2.2 Morphological and molecular changes of peritubular capillaries (III) 
 
Mutations in podocyte-specific nephrin are known to affect only glomeruli in NPHS1 kidneys, 
raising the interesting question of how the glomerular injury is transmitted to the tubulointerstitium 
lead to renal fibrosis. The vasculature of the kidney cortex has a unique architecture, where PTCs 
receive the blood from the efferent arteriole of the ―parent‖ glomerulus, i.e. the glomerulus of the 
same nephron (Nangaku 2006). Several lines of evidence suggest that the microvasculature may 
play a very important role in progression of renal disease. 
 
The peritubular space and capillaries were narrowed and the endothelial surface area was slightly 
reduced in NPHS1 kidneys, suggesting PTC injury and hypoperfusion. PTC density was also 
reduced in NPHS1 kidneys, and it was correlated with the interstitial fibrosis. PTC injury and loss 
are known to lead to impaired delivery of oxygen and nutrients to the tubules and interstitial cells 
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involved in the development of ischaemia. The increased expression of HIF-1 in the 
tubulointerstitium of NPHS1 kidneys implicated low oxygen tension and hypoxia. Despite the 
impaired blood flow and tubulointerstitial ischaemia, we did not detect endothelial cell activation or 
vascular thrombi in PTCs of NPHS1 kidneys. One may summarize that the reduced blood flow in 
the narrowed glomerular capillaries and the obliteration of the atherosclerotic arterioles may lead to 
hypoperfusion and PTC injury, resulting in interstitial hypoxia and tubular damage (Kuusniemi et 
al. 2005, 2006).  
 
Histological studies of human kidneys have confirmed that the loss of peritubular capillaries is 
correlated with tubular atrophy and interstitial fibrosis (Bohle et al. 1996, Choi et al. 2000). 
Irreversible PTC injury and loss of identifiable PTCs are also accompanied by progression of 
tubular damage and interstitial fibrosis in experimental models of nephropathy (Ohashi 2000, Sun 
2006) and in chronic allograft nephropathy (Ishii et al. 2005). Interestingly, we found an association 
between PTC loss and increased expression of cytoskeleton protein vimentin in NPHS1 kidneys. 
Early vimentin expression has recently been reported in some kidney disorders and renal transplants 
(Sanai et al. 2000, Suzuki et al. 2001, Hertig et al. 2008), and the association of this with PTC loss 
is interesting.  
 
In general, tubular epithelium can tolerate hypoxia quite well, and it has the potential to regenerate. 
However, the hypoxic environment reduces the capacity for cell survival. The survival of tubular 
epithelial cells depends upon a complicated interplay between peritubular capillaries, interstitial 
cells and tubular cells themselves. Experimental data have shown that hypoxia may drive renal 
fibrosis and fibroblast activation (Manotham et al. 2004). The activation of hypoxic signalling 
through HIF is also emerging as an important trigger and modulator of EMT (Haase 2009). 
Experimental studies have revealed that rarefaction of peritubular capillaries precedes the 
 87 
development of tubulointerstitial fibrosis (Basile et al. 2001, Matsumoto et al. 2004). This idea was 
supported by studies with animal models of nephrosis, which suggested that loss of peritubular 
capillaries and decreased peritubuluar blood flow was followed by hypoxia (confirmed by 
significantly increased expression of HIF-1) (Kairaitis et al. 2005, Sun et al. 2006). 
 
It has also been hypothesized that the tubular epithelium itself may play a role in maintaining 
peritubular capillaries since it has been recognized as a site of VEGF production. The expression of 
angiogenic VEGF is considered indispensable for endothelial cell survival and repair during the 
course of renal disease (Ostendorf et al. 1999, Kang et al. 2001). Interestingly, low expression of 
VEGF was detected in NPHS1 kidneys. PTC regression with local VEGF depletion has also been 
shown to correlate with progressive tubulointerstitial scarring in experimental obstructive 
nephropathy (Ohashi et al. 2002) and in human diabetic kidneys (Lindenmeyer et al. 2007).   
 
In addition to hypoxia, proteinuria has an important role in the progression of renal fibrosis (Tarver-
Carr et al. 2000, de Zeeuw et al. 2004). Mesangial expansion, glomerular capillary obliteration and 
periglomerular inflammation seem to precede tubulointerstitial damage in NPHS1 kidneys, 
indicating that hypoperfusion, rather than proteinuria, is the key regulator of interstitial fibrosis 
(Kuusniemi et al 2005, 2006). Many clinical and animal model experiments have revealed that 
tubulointerstitial damage rather than glomerular damage correlates with the renal failure 
(Manotham et al. 2004, Ohashi et al. 2000). In a model of subacute renal disease, the reduction of 
parent glomerular capillaries and hypoxic insults had a stronger influence on PTC flow and 
tubulointerstitial damage than proteinuria alone (Wong et al. 2008).  
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3. RAS and oxidative stress in NPHS1 kidneys (IV) 
3.1 Expression of Ang II and other RAS-related molecules (IV) 
 
RAS has been traditionally considered as an endocrine system maintaining blood pressure regulated 
by Ang II-induced vasoconstriction and aldosterone-mediated sodium retention in the collecting 
duct. However, several lines of evidence show that RAS also plays an important role in many 
pathophysiological changes that lead to the progression of renal disease (Rüster et al. 2006). The 
expression of Ang II, the primary effector of RAS, was upregulated (almost two-fold) in NPHS1 
kidneys, and the expression was mainly localized at the proximal tubuli. However, the expression of 
other RAS molecules; ACE, ACE2, AT1 and AT2 was almost equal in NPHS1 and control kidneys. 
mRNA transcript levels of ACE, ACE2, AT1 and AT2 were upregulated, suggesting a fast turn-
over rate for RAS proteins in NPHS1 kidneys.  
 
The activation tubular of Ang II expression in NPHS1 kidneys refers to activation of local RAS 
production. Previous reports have shown that some renal cells, such as tubular epithelial cells, 
macrophages and fibroblasts, have the machinery for the synthesis of Ang II (Ruiz et al. 1997, 
Gilbert et al. 1999). This system is called local RAS, and it is activated directly and indirectly by 
renal injury. In NPHS1 kidneys, the activation of Ang II may be due to tubular epithelial albumin 
reabsorption, which activates the tubular RAS production (Beutler et al. 2003).  This most probably 
explains the upregulation of Ang II in the NPHS1 kidneys with heavy and constant protein leakage 
in the glomeruli. We have previously observed rarefaction of peritubular capillaries and signs of 
hypoxia in the NPHS1 kidneys, which may also be involved in this upregulation (Kaukinen et al. 
2009). Almost all Ang II-induced physiological and pathophysiological functions are mediated by 
AT1 receptor, while the role of the AT2 receptor is less clear (Wolf et al. 2003). AT1 receptor 
expression is suppressed by high Ang II concentrations (Wolf et al. 2003). We did not observe 
changes in the expression of these receptors in NPHS1 kidneys. 
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The upregulation of Ang II expression may play an important role in pathophysiological processes 
associated with proteinuria in NPHS1 kidneys. Ang II can increase vascular tone by inducing 
contraction of vascular smooth muscle cells and mesangial cells, or by promoting cellular 
proliferation and ECM synthesis through direct effects (both haemodynamic and non-
haemodynamic) or via induction of growth factors such as TGF-. These findings are also 
manifested in diabetic nephropathy (Rüster et al. 2006). 
 
3.2 NAD(P)H oxidase and oxidative stress (IV) 
Ang II is also an important mediator in oxidative stress. It has been suggested that Ang II stimulates 
intracellular formation of ROS by activating several subunits of NAD(P)H oxidase, such as Nox1, 
p47phox, p67phox and p22phox, in mitochondria (Sachse et al. 2007). Upregulation in the 
expression of various subunits of NAD(P)H oxidase under oxidative stress has been reported in 
several kidney diseases (Heitzer et al. 1999, Onozato et al. 2002, Nosratola et al. 2003, Thallas-
Bonke et al. 2007, Kocer et al. 2008). Interestingly, NPHS1 kidneys exhibited a significant 
elevation of the p22phox subunit of NAP(D)H oxidase, indicating the presence of ROS. In the 
NPHS1 kidneys, immunohistochemistry for p22phox revealed coexpression of Ang II and 
NAD(P)H  in a few foci of inflammatory cells, but not in tubular cells, speaking for a more indirect 
association between these molecular pathways. 
 
NAD(P)H oxidase is a cytosolic enzyme complex initially discovered in neutrophils (phagocytic cells), 
where it plays a vital role in non-specific host-pathogen defence by producing millimolar quantities of 
O2
-
. NAD(P)H oxidase is present not only in phagocytic cells but also in non-phagocytic renal cell 
types such as mesangial and proximal tubular cells, vascular smooth muscle cells, endothelial cells and 
fibroblasts (Griedling et al. 1994). Surprisingly, in NPHS1 kidneys, the expression of p22phox was 
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mainly localized within interstitial inflammatory cells, and specifically in some neutrophilic 
granulocytes, monocytes and macrophages. No coexpression of p22phox was found with tubular or 
epithelial cell marker cytokeratin, endothelial cell markers CD31 and CD34, or myofibroblast marker 
SMA. The renal isoform of NAD(P)H oxidase, NOX4, has been reported to be constitutionally 
expressed, especially in endothelial cells (Frey et al.  2009), which was not evident in this work.  These 
data suggest that neutrophilic granulocytes, monocytes and macrophages are the inflammatory cell 
types responsible for ROS production in NPHS1 kidneys.  According to our previous results, the most 
abundant inflammatory cells in NPHS1 kidneys were monocytes/macrophages and T lymphocytes, 
while the most abundant chemokines were neutrophil-activating protein-2 (NAP-2), macrophage-
inhibiting factor (MIF) and monocyte chemoattractant protein-1 (MCP-1) (Kuusniemi et al. 2005).  
 
The recruitment of inflammatory cells into the glomerulus and tubulointerstitium plays an 
important role in the progression of renal disease. Ang II stimulates activation of proinflammatory 
transcription factor NF-B, which further leads to high expression of MCP-1, RANTES and other 
proinflammatory cytokines. However, it has been shown that albumin itself is a strong stimulus for 
H2O2 production, which also leads to the activation of NF-B-dependent signalling pathways 
(Morigi et al. 2002, Tang et al. 2003). It is also known that hyperlipidaemia activates xanthine 
oxidase and the generation of oxidants, resulting in the upregulation of MCP-1 and VCAM-1 and 
macrophage infiltration in the tubulointerstitial region (Gwinner et al. 2006).  
 
Under normal physiological conditions, a homeostatic balance exists between the formation of ROS 
(e.g. superoxide) and their removal by endogenous antioxidant compounds (Finkel et al. 2000, 
Paravicini et al. 2008). Oxidative stress occurs when this balance is disrupted by excessive 
production of ROS and/or by inadequate antioxidant defence. Oxidative stress has emerged as a 
major feature in chronic renal failure. It is believed to be important in various glomerular disorders 
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(such as minimal change disease, membranous glomerulonephritis, diabetic nephropathy and 
neutrophil-induced damage), ischemic or toxic acute renal failure and obstructive nephropathy 
(Iwasaki 1990, Klahr 1997, Shah et al. 2007).  
 
Due to the very short half-lives of ROS, their direct measurement is impossible. Therefore, indirect 
methods to measure scavenger antioxidant enzymes, including superoxide dismutase (SOD) and 
catalase (CAT), or lipid and protein oxidation byproducts are commonly used to evaluate oxidative 
stress (Vaziri et al. 2003, Araujo  et al. 2006). The cortex of NPHS1 kidneys exhibited a reduction 
in the SOD and CAT enzyme activities. In addition, the activity of lipid oxidation was increased in 
NPHS1 kidneys relative to human and porcine controls. Elevated mRNA transcript levels were 
observed for molecules related to antioxidant defence, hyperlipidaemia and lipid peroxidation. 
Strong expression of MPO and very low levels of free glutathione were recently observed in the 
cortex of NPHS1 kidneys, indicating the presence of oxidative stress (Kuusniemi et al .2005). MPO 
is known to generate a powerful oxidant, hypochlorous acid (HOCl), which may cause permanent 
tissue damage, whereas glutathione is a major antioxidant in human tissues (Pullar et al. 1999).  
Altogether, these data indicate the presence of oxidative stress in NPHS1 kidneys. 
 
In general, reports of the expression of antioxidant enzymes participating in free radical scavenging 
have described controversial results. However, downregulated SOD activity and elevated NAD(P)H 
oxidase expression have been associated with oxidative stress in an experimental model of chronic 
renal failure (Vaziri  et al. 2003) and diabetic nephropathy (Hayden et al. 2005). Reduced 
antioxidant enzyme activity and blood glutathione together with increased malondialdehyde (MDA) 
concentration were associated with a higher degree of oxidative stress in children with chronic renal 
failure. Reduced antioxidant enzyme activity in kidneys may be due to their increased consumption 
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during free radical production, uremic toxicity or deficiencies of trace elements (Cu, Se, Zn) (Ece et 
al. 2006). 
 
4. Conclusions and future prospects 
 
The findings presented in this thesis provide novel insights into the complicated mechanisms of 
glomerular proteinuria. We searched for prognostic molecular markers and the key cellular 
signalling pathways leading to glomerulosclerosis and tubulointerstitial fibrosis in proteinuric 
NPHS1 kidneys. Mesangial matrix expansion was associated with the overexpression of TGF-, the 
upregulation of TGF- type II receptor and the activation of the downstream Smad signalling 
pathway. Therapeutic targeting of these molecular pathways may be an important area of research 
in the clinical treatment of NPHS1 patients. Our studies also demonstrated that hypoxia is strongly 
involved in the pathology of NPHS1. Oxygen-dependent activation of prolyl hydroxylases (PHDs) 
are known to regulate the amount of HIF transcription factor by degradation. Therefore, PHD 
inhibitors may be a focus in novel therapeutic approaches against hypoxia in NPHS1 kidneys. 
Increased oxidative stress further exacerbates renal injury. Conventional and catalytic antioxidants 
may prevent or delay the onset of NPHS1. A combination of different strategies to prevent 
overproduction of ROS and to increase the removal of preformed ROS may also prove to be 
effective in preventing the development and progression of NPHS1. Further research is, however, 
needed to fully understand the progression of the disease at the molecular and cellular levels in 
order to develop powerful medical drugs for clinical treatment. 
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SUMMARY 
 
The main results of this study can be summarized as follows: 
I. Progressive mesangial expansion in NPHS1 kidneys is caused by MC hyperplasia and the 
accumulation of ECM proteins. Expansion of the extracellular matrix was caused by the 
accumulation of a normal MC product, collagen IV. However, no significant changes in 
MC phenotype or ECM composition were observed. The expression levels of TGF- and 
its downstream mediator CTGF were upregulated in NPHS1 kidneys. The activation of the 
TGF- signalling pathway suggests that TGF- has an important role in regulating 
glomerulosclerosis in NPHS1 kidneys. 
II. Endotheliosis was the main ultrastructural lesion observed in the endothelium of NPHS1 
glomeruli. The glomerular endothelial cells did not show significant signs of injury.  The 
abundant expression of VEGF and its transcription factor HIF-1 was in accordance with 
the preserved structure of the endothelium in NPHS1 kidneys. The expression of ICAM-1 
and several chemokines was upregulated in NPHS1 kidneys. However, the recruitment of 
leukocytes carrying ligands for the major endothelial adhesion molecules was modest in 
NPHS1 glomeruli. 
III. Hypoperfusion of PTCs and tubulointerstitial hypoxia were evident in NPHS1 kidneys, 
indicating that these may play an important role in the rapid progression of fibrosis in the 
kidneys of NPHS1 patients. Vimentin expression was an early marker for tubulointerstitial 
lesions associated with PTC loss. The inflammatory response of PTCs was observed as an 
upregulation of ICAM-1.  
IV. Upregulation of Ang II expression was obvious, emphasizing its role in the 
pathophysiology of NPHS1. Excessive oxidative stress was evident in NPHS1 kidneys, 
manifested as an increased expression of p22phox, superoxide production, lipid oxide 
peroxidation and reduced antioxidant activity.  
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